{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:41:30Z","timestamp":1792788090797,"version":"4.5.0"},"reference-count":400,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":83,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Haikou City Key Science and Technology Plan Projects","award":["2025-013"],"award-info":[{"award-number":["2025-013"]}]},{"name":"The Innovation Platform for Academicians of Hainan Province","award":["SQ2021YSPTJXRWS0103"],"award-info":[{"award-number":["SQ2021YSPTJXRWS0103"]}]},{"name":"Hainan Provincial Joint Key Project on Health Science and Technology Innovation","award":["WSJK2025ZD211"],"award-info":[{"award-number":["WSJK2025ZD211"]}]},{"name":"Natural Science Foundation of Hunan Province","award":["2024JJ9290"],"award-info":[{"award-number":["2024JJ9290"]}]},{"name":"National Natural Science Foundation of China","award":["82460479"],"award-info":[{"award-number":["82460479"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Guangxi Natural Science Foundation","award":["2023GXNSFAA026234"],"award-info":[{"award-number":["2023GXNSFAA026234"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>WD40-repeat (WDR) proteins constitute one of the largest and most functionally diverse scaffold families in eukaryotes. By folding tandem WD repeats into \u03b2-propeller domains, they provide modular interaction surfaces that assemble multi-protein complexes governing transcription and epigenetic control, ubiquitin-dependent proteostasis, RNA metabolism, and cell-cycle progression. Despite their pervasive involvement in oncogenic signaling and hallmark cancer phenotypes, the cancer field still lacks an integrated framework that connects WDR structural logic to context-dependent mechanisms and, critically, to actionable biomarkers and therapeutic strategies; existing evidence remains dispersed across tumor types and molecular pathways. This review synthesizes current knowledge to address that gap. We first summarize core structural principles of WD40 \u03b2-propellers and explain how multivalent binding and partner selection enable WDR proteins to function as assembly platforms in oncogenic networks. We then consolidate mechanistic evidence showing how representative WDR proteins shape malignant state transitions, including sustained proliferation, survival under stress, epigenetic plasticity, invasion and metastasis, and therapy resistance, by rewiring chromatin programs, ubiquitination circuits, and RNA and translation outputs across cancers. Finally, we highlight translational progress and opportunities. Overall, this review integrates the fragmented WDR research into a clinically oriented framework that clarifies their potential as biomarkers for early detection, stratified diagnosis, and treatment-response prediction, and delineates druggable entry points and rational combination strategies, thereby providing a translational roadmap to enable more precise cancer diagnosis and more effective targeted therapies in the future.<\/jats:p>","DOI":"10.1186\/s12943-026-02718-2","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T10:25:54Z","timestamp":1782555954000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The role of the WD40-repeat protein family in cancer"],"prefix":"10.1186","volume":"25","author":[{"given":"Jiale","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qisheng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duorong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximo","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xindong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongping","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiachong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changfeng","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zigui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhai","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"key":"2718_CR1","doi-asserted-by":"crossref","unstructured":"Hu Y, Bruinstroop E, Hollenberg AN, Fliers E, Boelen A. The role of WD40 repeat-containing proteins in endocrine (dys)function. J Mol Endocrinol. 2023;71(1):e220217.","DOI":"10.1530\/JME-22-0217"},{"issue":"11","key":"2718_CR2","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/nrd.2017.179","volume":"16","author":"M Schapira","year":"2017","unstructured":"Schapira M, Tyers M, Torrent M, Arrowsmith CH. WD40 repeat domain proteins: a novel target class? Nat Rev Drug Discov. 2017;16(11):773\u201386.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"2718_CR3","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1021\/acs.jmedchem.4c02010","volume":"68","author":"S Ackloo","year":"2025","unstructured":"Ackloo S, Li F, Szewczyk M, Seitova A, Loppnau P, Zeng H, et al. A target class ligandability evaluation of WD40 repeat-containing proteins. J Med Chem. 2025;68(2):1092\u2013112.","journal-title":"J Med Chem"},{"issue":"3","key":"2718_CR4","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.molcel.2015.02.028","volume":"58","author":"LR Thomas","year":"2015","unstructured":"Thomas LR, Wang Q, Grieb BC, Phan J, Foshage AM, Sun Q, et al. Interaction with WDR5 promotes target gene recognition and tumorigenesis by MYC. Mol Cell. 2015;58(3):440\u201352.","journal-title":"Mol Cell"},{"issue":"2","key":"2718_CR5","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.tcb.2024.06.001","volume":"35","author":"H Wang","year":"2025","unstructured":"Wang H, Helin K. Roles of H3K4 methylation in biology and disease. Trends Cell Biol. 2025;35(2):115\u201328.","journal-title":"Trends Cell Biol"},{"issue":"5","key":"2718_CR6","doi-asserted-by":"publisher","first-page":"189140","DOI":"10.1016\/j.bbcan.2024.189140","volume":"1879","author":"Y Qi","year":"2024","unstructured":"Qi Y, Rezaeian AH, Wang J, Huang D, Chen H, Inuzuka H, et al. Molecular insights and clinical implications for the tumor suppressor role of SCF(FBXW7) E3 ubiquitin ligase. Biochim Biophys Acta Rev Cancer. 2024;1879(5):189140.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"14","key":"2718_CR7","doi-asserted-by":"publisher","first-page":"17854","DOI":"10.18632\/oncotarget.7439","volume":"7","author":"Y Ye","year":"2016","unstructured":"Ye Y, Tang X, Sun Z, Chen S. Upregulated WDR26 serves as a scaffold to coordinate PI3K\/ AKT pathway-driven breast cancer cell growth, migration, and invasion. Oncotarget. 2016;7(14):17854\u201369.","journal-title":"Oncotarget"},{"issue":"3\u20134","key":"2718_CR8","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1101\/gad.349803.122","volume":"37","author":"K Mitchell","year":"2023","unstructured":"Mitchell K, Sprowls SA, Arora S, Shakya S, Silver DJ, Goins CM, et al. WDR5 represents a therapeutically exploitable target for cancer stem cells in glioblastoma. Genes Dev. 2023;37(3\u20134):86\u2013102.","journal-title":"Genes Dev"},{"issue":"5","key":"2718_CR9","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.celrep.2012.04.002","volume":"1","author":"H Fukushima","year":"2012","unstructured":"Fukushima H, Matsumoto A, Inuzuka H, Zhai B, Lau AW, Wan L, et al. SCF(Fbw7) modulates the NFkB signaling pathway by targeting NFkB2 for ubiquitination and destruction. Cell Rep. 2012;1(5):434\u201343.","journal-title":"Cell Rep"},{"issue":"5","key":"2718_CR10","doi-asserted-by":"publisher","first-page":"115626","DOI":"10.1016\/j.celrep.2025.115626","volume":"44","author":"H Fukushima","year":"2025","unstructured":"Fukushima H, Matsumoto A, Inuzuka H, Zhai B, Lau AW, Wan L, et al. SCF(Fbw7) Modulates the NF\u03baB signaling pathway by targeting NF\u03baB2 for ubiquitination and destruction. Cell Rep. 2025;44(5):115626.","journal-title":"Cell Rep"},{"issue":"1","key":"2718_CR11","doi-asserted-by":"publisher","first-page":"13666","DOI":"10.1038\/s41598-024-82867-w","volume":"15","author":"H Lu","year":"2025","unstructured":"Lu H, Zhang B, Li W, Wang Z. Deciphering the prognostic significance of WDR77 in gliomas: a comprehensive analysis. Sci Rep. 2025;15(1):13666.","journal-title":"Sci Rep"},{"issue":"1","key":"2718_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40001-023-01605-6","volume":"29","author":"X Cheng","year":"2024","unstructured":"Cheng X, Liu Z, Chang H, Liang W, Li P, Gao Y. WD repeat domain 76 predicts poor prognosis in lower grade glioma and provides an original target for immunotherapy. Eur J Med Res. 2024;29(1):13.","journal-title":"Eur J Med Res"},{"issue":"2","key":"2718_CR13","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/0014-5793(92)80751-2","volume":"307","author":"L van der Voorn","year":"1992","unstructured":"van der Voorn L, Ploegh HL. The WD-40 repeat. FEBS Lett. 1992;307(2):131\u20134.","journal-title":"FEBS Lett"},{"issue":"6495","key":"2718_CR14","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/371297a0","volume":"371","author":"EJ Neer","year":"1994","unstructured":"Neer EJ, Schmidt CJ, Nambudripad R, Smith TF. The ancient regulatory-protein family of WD-repeat proteins. Nature. 1994;371(6495):297\u2013300.","journal-title":"Nature"},{"issue":"10","key":"2718_CR15","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.tibs.2010.04.003","volume":"35","author":"CU Stirnimann","year":"2010","unstructured":"Stirnimann CU, Petsalaki E, Russell RB, M\u00fcller CW. WD40 proteins propel cellular networks. Trends Biochem Sci. 2010;35(10):565\u201374.","journal-title":"Trends Biochem Sci"},{"issue":"6","key":"2718_CR16","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/0092-8674(95)90220-1","volume":"83","author":"MA Wall","year":"1995","unstructured":"Wall MA, Coleman DE, Lee E, I\u00f1iguez-Lluhi JA, Posner BA, Gilman AG, et al. The structure of the G protein heterotrimer Gi alpha 1 beta 1 gamma 2. Cell. 1995;83(6):1047\u201358.","journal-title":"Cell"},{"issue":"6563","key":"2718_CR17","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/379369a0","volume":"379","author":"J Sondek","year":"1996","unstructured":"Sondek J, Bohm A, Lambright DG, Hamm HE, Sigler PB. Crystal structure of a G-protein beta gamma dimer at 2.1A resolution. Nature. 1996;379(6563):369\u201374.","journal-title":"Nature."},{"issue":"5","key":"2718_CR18","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0968-0004(99)01384-5","volume":"24","author":"TF Smith","year":"1999","unstructured":"Smith TF, Gaitatzes C, Saxena K, Neer EJ. The WD repeat: a common architecture for diverse functions. Trends Biochem Sci. 1999;24(5):181\u20135.","journal-title":"Trends Biochem Sci"},{"issue":"6","key":"2718_CR19","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/S0959-440X(99)00035-4","volume":"9","author":"V F\u00fcl\u00f6p","year":"1999","unstructured":"F\u00fcl\u00f6p V, Jones DT. Beta propellers: structural rigidity and functional diversity. Curr Opin Struct Biol. 1999;9(6):715\u201321.","journal-title":"Curr Opin Struct Biol"},{"issue":"3","key":"2718_CR20","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s13238-011-1018-1","volume":"2","author":"C Xu","year":"2011","unstructured":"Xu C, Min J. Structure and function of WD40 domain proteins. Protein Cell. 2011;2(3):202\u201314.","journal-title":"Protein Cell"},{"issue":"2\u20133","key":"2718_CR21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1006\/jsbi.2001.4392","volume":"134","author":"MA Andrade","year":"2001","unstructured":"Andrade MA, Perez-Iratxeta C, Ponting CP. Protein repeats: structures, functions, and evolution. J Struct Biol. 2001;134(2\u20133):117\u201331.","journal-title":"J Struct Biol"},{"issue":"6","key":"2718_CR22","doi-asserted-by":"publisher","first-page":"e65705","DOI":"10.1371\/journal.pone.0065705","volume":"8","author":"Y Wang","year":"2013","unstructured":"Wang Y, Jiang F, Zhuo Z, Wu XH, Wu YD. A method for WD40 repeat detection and secondary structure prediction. PLoS ONE. 2013;8(6):e65705.","journal-title":"PLoS ONE"},{"issue":"8","key":"2718_CR23","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1073\/pnas.0508121103","volume":"103","author":"M Wang","year":"2006","unstructured":"Wang M, Wales TE, Fitzgerald MC. Conserved thermodynamic contributions of backbone hydrogen bonds in a protein fold. Proc Natl Acad Sci U S A. 2006;103(8):2600\u20134.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"2718_CR24","doi-asserted-by":"publisher","first-page":"9041","DOI":"10.1074\/jbc.273.15.9041","volume":"273","author":"I Garcia-Higuera","year":"1998","unstructured":"Garcia-Higuera I, Gaitatzes C, Smith TF, Neer EJ. Folding a WD repeat propeller. Role of highly conserved aspartic acid residues in the G protein beta subunit and Sec13. J Biol Chem. 1998;273(15):9041\u20139.","journal-title":"J Biol Chem."},{"issue":"8","key":"2718_CR25","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1073\/pnas.1419595112","volume":"112","author":"RL Plimpton","year":"2015","unstructured":"Plimpton RL, Cu\u00e9llar J, Lai CW, Aoba T, Makaju A, Franklin S, et al. Structures of the G\u03b2-CCT and PhLP1-G\u03b2-CCT complexes reveal a mechanism for G-protein \u03b2-subunit folding and G\u03b2\u03b3 dimer assembly. Proc Natl Acad Sci U S A. 2015;112(8):2413\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2718_CR26","doi-asserted-by":"publisher","first-page":"10585","DOI":"10.1038\/s41598-017-11115-1","volume":"7","author":"XJ Hu","year":"2017","unstructured":"Hu XJ, Li T, Wang Y, Xiong Y, Wu XH, Zhang DL, et al. Prokaryotic and highly-repetitive WD40 proteins: a systematic Study. Sci Rep. 2017;7(1):10585.","journal-title":"Sci Rep"},{"issue":"5","key":"2718_CR27","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s10930-018-9785-7","volume":"37","author":"BP Jain","year":"2018","unstructured":"Jain BP, Pandey S. WD40 repeat proteins: signalling scaffold with diverse functions. Protein J. 2018;37(5):391\u2013406.","journal-title":"Protein J"},{"issue":"D1","key":"2718_CR28","doi-asserted-by":"publisher","first-page":"D339","DOI":"10.1093\/nar\/gku1023","volume":"43","author":"Y Wang","year":"2014","unstructured":"Wang Y, Hu X-J, Zou X-D, Wu X-H, Ye Z-Q, Wu Y-D. WDSPdb: a database for WD40-repeat proteins. Nucleic Acids Res. 2014;43(D1):D339-44.","journal-title":"Nucleic Acids Res"},{"key":"2718_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/srep39262","volume":"6","author":"XD Zou","year":"2016","unstructured":"Zou XD, Hu XJ, Ma J, Li T, Ye ZQ, Wu YD. Genome-wide analysis of WD40 protein family in human. Sci Rep. 2016;6:39262.","journal-title":"Sci Rep"},{"issue":"6","key":"2718_CR30","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/nrm3582","volume":"14","author":"JR Skaar","year":"2013","unstructured":"Skaar JR, Pagan JK, Pagano M. Mechanisms and function of substrate recruitment by F-box proteins. Nat Rev Mol Cell Biol. 2013;14(6):369\u201381.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"2718_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/2045-3701-4-13","volume":"4","author":"C Gao","year":"2014","unstructured":"Gao C, Xiao G, Hu J. Regulation of Wnt\/\u03b2-catenin signaling by posttranslational modifications. Cell Biosci. 2014;4(1):13.","journal-title":"Cell Biosci"},{"key":"2718_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fpls.2015.01108","volume":"6","author":"JC Miller","year":"2016","unstructured":"Miller JC, Chezem WR, Clay NK. Ternary WD40 repeat-containing protein complexes: evolution, composition and roles in plant immunity. Front Plant Sci. 2016;6:2015.","journal-title":"Front Plant Sci"},{"key":"2718_CR33","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1146\/annurev-biochem-090120-013613","volume":"90","author":"JW Harper","year":"2021","unstructured":"Harper JW, Schulman BA. Cullin-RING ubiquitin ligase regulatory circuits: a quarter century beyond the F-box hypothesis. Annu Rev Biochem. 2021;90:403\u201329.","journal-title":"Annu Rev Biochem"},{"issue":"7847","key":"2718_CR34","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41586-021-03197-9","volume":"590","author":"D Horn-Ghetko","year":"2021","unstructured":"Horn-Ghetko D, Krist DT, Prabu JR, Baek K, Mulder MPC, Kl\u00fcgel M, et al. Ubiquitin ligation to F-box protein targets by SCF-RBR E3\u2013E3 super-assembly. Nature. 2021;590(7847):671\u20136.","journal-title":"Nature"},{"key":"2718_CR35","doi-asserted-by":"crossref","unstructured":"Nakagawa M, Nakagawa T. CUL4-based ubiquitin ligases in chromatin regulation: an evolutionary perspective. Cells.\u00a02025;14(2):63.","DOI":"10.3390\/cells14020063"},{"issue":"1","key":"2718_CR36","doi-asserted-by":"publisher","first-page":"10074","DOI":"10.1038\/s41467-024-54398-5","volume":"15","author":"A H\u00f6fler","year":"2024","unstructured":"H\u00f6fler A, Yu J, Yang J, Zhang Z, Chang L, McLaughlin SH, et al. Cryo-EM structures of apo-APC\/C and APC\/C(CDH1:EMI1) complexes provide insights into APC\/C regulation. Nat Commun. 2024;15(1):10074.","journal-title":"Nat Commun"},{"issue":"2","key":"2718_CR37","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.tibs.2025.11.003","volume":"51","author":"MY Bhat","year":"2026","unstructured":"Bhat MY, Liu X. Emerging structural insights into PRC2 function in development and disease. Trends Biochem Sci. 2026;51(2):172\u201386.","journal-title":"Trends Biochem Sci"},{"key":"2718_CR38","doi-asserted-by":"crossref","unstructured":"Gurung R, Om D, Pun R, Hyun S, Shin D. Recent progress in modulation of WD40-repeat domain 5 protein (WDR5): inhibitors and degraders. Cancers (Basel).\u00a02023;15(15):3910.","DOI":"10.3390\/cancers15153910"},{"key":"2718_CR39","doi-asserted-by":"publisher","first-page":"1276612","DOI":"10.3389\/fmolb.2023.1276612","volume":"10","author":"L Cai","year":"2023","unstructured":"Cai L, Liu B, Cao Y, Sun T, Li Y. Unveiling the molecular structure and role of RBBP4\/7: implications for epigenetic regulation and cancer research. Front Mol Biosci. 2023;10:1276612.","journal-title":"Front Mol Biosci"},{"issue":"1","key":"2718_CR40","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.molcel.2019.05.007","volume":"75","author":"X Bi","year":"2019","unstructured":"Bi X, Xu Y, Li T, Li X, Li W, Shao W, et al. RNA targets ribogenesis factor WDR43 to chromatin for transcription and pluripotency control. Mol Cell. 2019;75(1):102-16.e9.","journal-title":"Mol Cell"},{"key":"2718_CR41","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.omtn.2023.08.005","volume":"33","author":"K Huang","year":"2023","unstructured":"Huang K, Zhang Y, Shi X, Yin Z, Zhao W, Huang L, et al. Cell-type-specific alternative polyadenylation promotes oncogenic gene expression in non-small cell lung cancer progression. Mol Ther Nucleic Acids. 2023;33:816\u201331.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"21","key":"2718_CR42","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1101\/gad.250993.114","volume":"28","author":"SL Chan","year":"2014","unstructured":"Chan SL, Huppertz I, Yao C, Weng L, Moresco JJ, Yates JR 3rd, et al. CPSF30 and Wdr33 directly bind to AAUAAA in mammalian mRNA 3\u2019 processing. Genes Dev. 2014;28(21):2370\u201380.","journal-title":"Genes Dev"},{"issue":"21","key":"2718_CR43","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1101\/gad.250985.114","volume":"28","author":"L Sch\u00f6nemann","year":"2014","unstructured":"Sch\u00f6nemann L, K\u00fchn U, Martin G, Sch\u00e4fer P, Gruber AR, Keller W, et al. Reconstitution of CPSF active in polyadenylation: recognition of the polyadenylation signal by WDR33. Genes Dev. 2014;28(21):2381\u201393.","journal-title":"Genes Dev"},{"key":"2718_CR44","doi-asserted-by":"publisher","first-page":"104599","DOI":"10.1016\/j.critrevonc.2024.104599","volume":"206","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Huang Z, Lu W, Liu Z. Alternative polyadenylation in cancer: molecular mechanisms and clinical application. Crit Rev Oncol Hematol. 2025;206:104599.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"2718_CR45","doi-asserted-by":"publisher","first-page":"3422","DOI":"10.1016\/j.ymthe.2021.08.005","volume":"29","author":"J Ma","year":"2021","unstructured":"Ma J, Han H, Huang Y, Yang C, Zheng S, Cai T, et al. METTL1\/WDR4-mediated m(7)G tRNA modifications and m(7)G codon usage promote mRNA translation and lung cancer progression. Mol Ther. 2021;29(12):3422\u201335.","journal-title":"Mol Ther"},{"issue":"15","key":"2718_CR46","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1038\/s41388-022-02250-9","volume":"41","author":"B Chen","year":"2022","unstructured":"Chen B, Jiang W, Huang Y, Zhang J, Yu P, Wu L, et al. N(7)-methylguanosine tRNA modification promotes tumorigenesis and chemoresistance through WNT\/\u03b2-catenin pathway in nasopharyngeal carcinoma. Oncogene. 2022;41(15):2239\u201353.","journal-title":"Oncogene"},{"issue":"1","key":"2718_CR47","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1038\/s41467-022-29125-7","volume":"13","author":"H Han","year":"2022","unstructured":"Han H, Yang C, Ma J, Zhang S, Zheng S, Ling R, et al. N(7)-methylguanosine tRNA modification promotes esophageal squamous cell carcinoma tumorigenesis via the RPTOR\/ULK1\/autophagy axis. Nat Commun. 2022;13(1):1478.","journal-title":"Nat Commun"},{"issue":"19","key":"2718_CR48","doi-asserted-by":"publisher","first-page":"11106","DOI":"10.1093\/nar\/gkx727","volume":"45","author":"M Rengasamy","year":"2017","unstructured":"Rengasamy M, Zhang F, Vashisht A, Song WM, Aguilo F, Sun Y, et al. The PRMT5\/WDR77 complex regulates alternative splicing through ZNF326 in breast cancer. Nucleic Acids Res. 2017;45(19):11106\u201320.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"2718_CR49","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/onc.2016.205","volume":"36","author":"H Chen","year":"2017","unstructured":"Chen H, Lorton B, Gupta V, Shechter D. A TGF\u03b2-PRMT5-MEP50 axis regulates cancer cell invasion through histone H3 and H4 arginine methylation coupled transcriptional activation and repression. Oncogene. 2017;36(3):373\u201386.","journal-title":"Oncogene"},{"key":"2718_CR50","doi-asserted-by":"publisher","first-page":"751792","DOI":"10.3389\/fonc.2021.751792","volume":"11","author":"L Mi","year":"2021","unstructured":"Mi L, Qi Q, Ran H, Chen L, Li D, Xiao D, et al. Suppression of ribosome biogenesis by targeting WD repeat domain 12 (WDR12) inhibits glioma stem-like cell growth. Front Oncol. 2021;11:751792.","journal-title":"Front Oncol"},{"issue":"11","key":"2718_CR51","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1177\/0022034516651077","volume":"95","author":"SB Sondalle","year":"2016","unstructured":"Sondalle SB, Baserga SJ, Yelick PC. The contributions of the ribosome biogenesis protein Utp5\/WDR43 to craniofacial development. J Dent Res. 2016;95(11):1214\u201320.","journal-title":"J Dent Res"},{"key":"2718_CR52","doi-asserted-by":"crossref","unstructured":"Brown IN, Lafita-Navarro MC, Conacci-Sorrell M. Regulation of nucleolar activity by MYC. Cells.\u00a02022;11(3):574.","DOI":"10.3390\/cells11030574"},{"issue":"1","key":"2718_CR53","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/1873-3468.14782","volume":"598","author":"T Proikas-Cezanne","year":"2024","unstructured":"Proikas-Cezanne T, Haas ML, Pastor-Maldonado CJ, Sch\u00fcssele DS. Human WIPI \u03b2-propeller function in autophagy and neurodegeneration. FEBS Lett. 2024;598(1):127\u201339.","journal-title":"FEBS Lett"},{"issue":"4","key":"2718_CR54","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/s41556-024-01373-3","volume":"26","author":"Y Zhu","year":"2024","unstructured":"Zhu Y, Fujimaki M, Snape L, Lopez A, Fleming A, Rubinsztein DC. Loss of WIPI4 in neurodegeneration causes autophagy-independent ferroptosis. Nat Cell Biol. 2024;26(4):542\u201351.","journal-title":"Nat Cell Biol"},{"issue":"6","key":"2718_CR55","doi-asserted-by":"publisher","first-page":"eadj8027","DOI":"10.1126\/sciadv.adj8027","volume":"10","author":"S Rao","year":"2024","unstructured":"Rao S, Skulsuppaisarn M, Strong LM, Ren X, Lazarou M, Hurley JH, et al. Three-step docking by WIPI2, ATG16L1, and ATG3 delivers LC3 to the phagophore. Sci Adv. 2024;10(6):eadj8027.","journal-title":"Sci Adv."},{"issue":"3","key":"2718_CR56","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1042\/BST20230897","volume":"52","author":"N Gopaldass","year":"2024","unstructured":"Gopaldass N, Mayer A. PROPPINs and membrane fission in the endo-lysosomal system. Biochem Soc Trans. 2024;52(3):1233\u201341.","journal-title":"Biochem Soc Trans"},{"key":"2718_CR57","doi-asserted-by":"crossref","unstructured":"Kolosov P, Biziaev N, Alkalaeva E. A duality of function: an integrative model of RACK1 as a switch between translational and signaling hubs. Int J Mol Sci. 2025;26(23):11733.","DOI":"10.3390\/ijms262311733"},{"issue":"24","key":"2718_CR58","doi-asserted-by":"publisher","first-page":"6845","DOI":"10.1016\/j.cell.2025.09.016","volume":"188","author":"W Oosterheert","year":"2025","unstructured":"Oosterheert W, Boiero Sanders M, Hofnagel O, Bieling P, Raunser S. Choreography of rapid actin filament disassembly by coronin, cofilin, and AIP1. Cell. 2025;188(24):6845-60.e27.","journal-title":"Cell"},{"key":"2718_CR59","doi-asserted-by":"crossref","unstructured":"Shor-Nareznoy Y, Caspi M, Lender Y, Wittenstein A, Soffer A, Elias H, et al. The role of the striatin family proteins in hippo signaling and cellular regulation. Cell Biosci. 2025;15(1):119.","DOI":"10.1186\/s13578-025-01461-3"},{"issue":"7","key":"2718_CR60","doi-asserted-by":"publisher","first-page":"5317","DOI":"10.1021\/acs.jmedchem.1c02148","volume":"65","author":"Y Huang","year":"2022","unstructured":"Huang Y, Sendzik M, Zhang J, Gao Z, Sun Y, Wang L, et al. Discovery of the clinical candidate MAK683: an EED-Directed, Allosteric, and Selective PRC2 inhibitor for the treatment of advanced malignancies. J Med Chem. 2022;65(7):5317\u201333.","journal-title":"J Med Chem"},{"issue":"8","key":"2718_CR61","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/nchembio.1859","volume":"11","author":"F Grebien","year":"2015","unstructured":"Grebien F, Vedadi M, Getlik M, Giambruno R, Grover A, Avellino R, et al. Pharmacological targeting of the Wdr5-MLL interaction in C\/EBP\u03b1 N-terminal leukemia. Nat Chem Biol. 2015;11(8):571\u20138.","journal-title":"Nat Chem Biol"},{"issue":"22","key":"2718_CR62","doi-asserted-by":"publisher","first-page":"4824","DOI":"10.1093\/bioinformatics\/btz460","volume":"35","author":"J Ma","year":"2019","unstructured":"Ma J, An K, Zhou JB, Wu NS, Wang Y, Ye ZQ, et al. WDSPdb: an updated resource for WD40 proteins. Bioinformatics. 2019;35(22):4824\u20136.","journal-title":"Bioinformatics"},{"key":"2718_CR63","doi-asserted-by":"publisher","first-page":"1596344","DOI":"10.3389\/fimmu.2025.1596344","volume":"16","author":"M Dai","year":"2025","unstructured":"Dai M, Chen S, Wang Y, Fan J, Pan X, Sang C, et al. F-box proteins at the crossroads of ubiquitination and tumor immunity: regulatory networks and immunotherapy strategies. Front Immunol. 2025;16:1596344.","journal-title":"Front Immunol"},{"issue":"5","key":"2718_CR64","doi-asserted-by":"publisher","first-page":"189169","DOI":"10.1016\/j.bbcan.2024.189169","volume":"1879","author":"J Cheng","year":"2024","unstructured":"Cheng J, Bin X, Tang Z. Cullin-RING Ligase 4 in cancer: structure, functions, and mechanisms. Biochim Biophys Acta Rev Cancer. 2024;1879(5):189169.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"6","key":"2718_CR65","doi-asserted-by":"publisher","first-page":"103986","DOI":"10.1016\/j.drudis.2024.103986","volume":"29","author":"Q Bao","year":"2024","unstructured":"Bao Q, Kumar A, Wu D, Zhou J. Targeting EED as a key PRC2 complex mediator toward novel epigenetic therapeutics. Drug Discov Today. 2024;29(6):103986.","journal-title":"Drug Discov Today"},{"issue":"8","key":"2718_CR66","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.7150\/ijms.91584","volume":"21","author":"Y Yang","year":"2024","unstructured":"Yang Y, Xie Q, Hu C, Xu J, Chen L, Li Y, et al. F-box proteins and gastric cancer: an update from functional and regulatory mechanism to therapeutic clinical prospects. Int J Med Sci. 2024;21(8):1575\u201388.","journal-title":"Int J Med Sci"},{"issue":"1","key":"2718_CR67","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1186\/s12964-025-02445-z","volume":"23","author":"J Cheng","year":"2025","unstructured":"Cheng J, Liu O, Bin X, Tang Z. F-box proteins in cancer: from cancer cells to the tumor microenvironment. Cell Commun Signal. 2025;23(1):433.","journal-title":"Cell Commun Signal"},{"issue":"21","key":"2718_CR68","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1101\/gad.1483206","volume":"20","author":"YJ He","year":"2006","unstructured":"He YJ, McCall CM, Hu J, Zeng Y, Xiong Y. DDB1 functions as a linker to recruit receptor WD40 proteins to CUL4-ROC1 ubiquitin ligases. Genes Dev. 2006;20(21):2949\u201354.","journal-title":"Genes Dev"},{"issue":"10","key":"2718_CR69","doi-asserted-by":"publisher","first-page":"100644","DOI":"10.1016\/j.mcpro.2023.100644","volume":"22","author":"J Raisch","year":"2023","unstructured":"Raisch J, Dubois ML, Groleau M, L\u00e9vesque D, Burger T, Jurkovic CM, et al. Pulse-SILAC and interactomics reveal distinct DDB1-CUL4-associated factors, cellular functions, and protein substrates. Mol Cell Proteomics. 2023;22(10):100644.","journal-title":"Mol Cell Proteomics"},{"issue":"3","key":"2718_CR70","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.molcel.2010.10.018","volume":"40","author":"N Pashkova","year":"2010","unstructured":"Pashkova N, Gakhar L, Winistorfer SC, Yu L, Ramaswamy S, Piper RC. WD40 repeat propellers define a ubiquitin-binding domain that regulates turnover of F box proteins. Mol Cell. 2010;40(3):433\u201343.","journal-title":"Mol Cell"},{"issue":"7","key":"2718_CR71","doi-asserted-by":"publisher","first-page":"194560","DOI":"10.1016\/j.bbagrm.2020.194560","volume":"1863","author":"H Jiang","year":"2020","unstructured":"Jiang H. The complex activities of the SET1\/MLL complex core subunits in development and disease. Biochim Biophys Acta Gene Regul Mech. 2020;1863(7):194560.","journal-title":"Biochim Biophys Acta Gene Regul Mech"},{"issue":"1","key":"2718_CR72","doi-asserted-by":"publisher","first-page":"2573998","DOI":"10.1080\/15592294.2025.2573998","volume":"20","author":"E Bahena-Culhuac","year":"2025","unstructured":"Bahena-Culhuac E, Hern\u00e1ndez-Somilleda M, Hern\u00e1ndez-Hern\u00e1ndez JM. Insights into WDR5: unveiling its functions, regulation, and impact on skeletal muscle. Epigenetics. 2025;20(1):2573998.","journal-title":"Epigenetics"},{"issue":"4","key":"2718_CR73","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/pro.3129","volume":"26","author":"M Vedadi","year":"2017","unstructured":"Vedadi M, Blazer L, Eram MS, Barsyte-Lovejoy D, Arrowsmith CH, Hajian T. Targeting human SET1\/MLL family of proteins. Protein Sci. 2017;26(4):662\u201376.","journal-title":"Protein Sci"},{"issue":"2","key":"2718_CR74","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.tcb.2024.06.001","volume":"35","author":"H Wang","year":"2025","unstructured":"Wang H, Helin K. Roles of H3K4 methylation in biology and disease. Trends Cell Biol. 2025;35(2):115\u201328.","journal-title":"Trends Cell Biol"},{"key":"2718_CR75","doi-asserted-by":"crossref","unstructured":"Weissmiller AM, Fesik SW, Tansey WP. WD repeat domain 5 inhibitors for cancer therapy: not what you think. J Clin Med. 2024;13(1):274.","DOI":"10.3390\/jcm13010274"},{"issue":"11","key":"2718_CR76","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/j.chembiol.2025.10.002","volume":"32","author":"M Zhang","year":"2025","unstructured":"Zhang M, Chen M, Li P, Min J. Therapeutic targeting of WDR5-MLL1 by EMBOW-derived peptides suppresses leukemia progression. Cell Chem Biol. 2025;32(11):1353-66.e6.","journal-title":"Cell Chem Biol"},{"issue":"4","key":"2718_CR77","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S0092-8674(04)00133-3","volume":"116","author":"V Perissi","year":"2004","unstructured":"Perissi V, Aggarwal A, Glass CK, Rose DW, Rosenfeld MG. A corepressor\/coactivator exchange complex required for transcriptional activation by nuclear receptors and other regulated transcription factors. Cell. 2004;116(4):511\u201326.","journal-title":"Cell"},{"issue":"1","key":"2718_CR78","first-page":"13","volume":"3","author":"JY Li","year":"2015","unstructured":"Li JY, Daniels G, Wang J, Zhang X. TBL1XR1 in physiological and pathological states. Am J Clin Exp Urol. 2015;3(1):13\u201323.","journal-title":"Am J Clin Exp Urol"},{"key":"2718_CR79","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.3389\/fonc.2024.1309687","volume":"14","author":"R Du","year":"2024","unstructured":"Du R, Li K, Guo K, Chen Z, Zhao X, Han L, et al. Two decades of a protooncogene TBL1XR1: from a transcription modulator to cancer therapeutic target. Front Oncol. 2024;14:2024.","journal-title":"Front Oncol"},{"issue":"2","key":"2718_CR80","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.cell.2020.05.049","volume":"182","author":"L Venturutti","year":"2020","unstructured":"Venturutti L, Teater M, Zhai A, Chadburn A, Babiker L, Kim D, et al. TBL1XR1 mutations drive extranodal lymphoma by inducing a pro-tumorigenic memory fate. Cell. 2020;182(2):297-316.e27.","journal-title":"Cell"},{"issue":"14","key":"2718_CR81","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021632","volume":"142","author":"J Kumar","year":"2023","unstructured":"Kumar J, Petrova-Drus K. Acute leukemia with predominantly myeloid differentiation and TBL1XR1::CSF1R fusion. Blood. 2023;142(14):1253.","journal-title":"Blood"},{"key":"2718_CR82","doi-asserted-by":"crossref","unstructured":"Afanasieva E, Chaudhuri I, Martin J, Hertle E, Ursinus A, Alva V, et al. Structural diversity of oligomeric \u03b2-propellers with different numbers of identical blades. Elife. 2019;8:e49853.","DOI":"10.7554\/eLife.49853"},{"issue":"10","key":"2718_CR83","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.tibs.2011.07.004","volume":"36","author":"CK Chen","year":"2011","unstructured":"Chen CK, Chan NL, Wang AH. The many blades of the \u03b2-propeller proteins: conserved but versatile. Trends Biochem Sci. 2011;36(10):553\u201361.","journal-title":"Trends Biochem Sci"},{"issue":"14","key":"2718_CR84","doi-asserted-by":"publisher","first-page":"5195","DOI":"10.1073\/pnas.1322892111","volume":"111","author":"MW Richards","year":"2014","unstructured":"Richards MW, Law EW, Rennalls LP, Busacca S, O\u2019Regan L, Fry AM, et al. Crystal structure of EML1 reveals the basis for Hsp90 dependence of oncogenic EML4-ALK by disruption of an atypical \u03b2-propeller domain. Proc Natl Acad Sci U S A. 2014;111(14):5195\u2013200.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"D1","key":"2718_CR85","doi-asserted-by":"publisher","first-page":"D523","DOI":"10.1093\/nar\/gkae997","volume":"53","author":"T Paysan-Lafosse","year":"2025","unstructured":"Paysan-Lafosse T, Andreeva A, Blum M, Chuguransky SR, Grego T, Pinto BL, et al. The Pfam protein families database: embracing AI\/ML. Nucleic Acids Res. 2025;53(D1):D523\u201334.","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"2718_CR86","doi-asserted-by":"publisher","first-page":"D444","DOI":"10.1093\/nar\/gkae1082","volume":"53","author":"M Blum","year":"2025","unstructured":"Blum M, Andreeva A, Florentino LC, Chuguransky SR, Grego T, Hobbs E, et al. InterPro: the protein sequence classification resource in 2025. Nucleic Acids Res. 2025;53(D1):D444\u201356.","journal-title":"Nucleic Acids Res"},{"key":"2718_CR87","unstructured":"UniProt Consortium. UniProt: the Universal Protein Knowledgebase in 2025. Nucleic Acids Res. 2025;53(D1):D609-D617."},{"issue":"6","key":"2718_CR88","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/S1097-2765(03)00234-X","volume":"11","author":"G Wu","year":"2003","unstructured":"Wu G, Xu G, Schulman BA, Jeffrey PD, Harper JW, Pavletich NP. Structure of a beta-TrCP1-Skp1-beta-catenin complex: destruction motif binding and lysine specificity of the SCF(beta-TrCP1) ubiquitin ligase. Mol Cell. 2003;11(6):1445\u201356.","journal-title":"Mol Cell"},{"key":"2718_CR89","doi-asserted-by":"publisher","first-page":"e13941","DOI":"10.7554\/eLife.13941","volume":"5","author":"CJ Millard","year":"2016","unstructured":"Millard CJ, Varma N, Saleh A, Morris K, Watson PJ, Bottrill AR, et al. The structure of the core NuRD repression complex provides insights into its interaction with chromatin. Elife. 2016;5:e13941.","journal-title":"Elife"},{"key":"2718_CR90","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2022.1011918","volume":"15","author":"M Almannai","year":"2022","unstructured":"Almannai M, Marafi D, El-Hattab AW. WIPI proteins: biological functions and related syndromes. Front Mol Neurosci. 2022;15:1011918.","journal-title":"Front Mol Neurosci"},{"issue":"16","key":"2718_CR91","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1093\/hmg\/ddad096","volume":"32","author":"T Shimizu","year":"2023","unstructured":"Shimizu T, Tamura N, Nishimura T, Saito C, Yamamoto H, Mizushima N. Comprehensive analysis of autophagic functions of WIPI family proteins and their implications for the pathogenesis of \u03b2-propeller associated neurodegeneration. Hum Mol Genet. 2023;32(16):2623\u201337.","journal-title":"Hum Mol Genet"},{"issue":"11","key":"2718_CR92","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1016\/j.celrep.2019.02.047","volume":"26","author":"ER Aho","year":"2019","unstructured":"Aho ER, Wang J, Gogliotti RD, Howard GC, Phan J, Acharya P, et al. Displacement of WDR5 from Chromatin by a WIN site inhibitor with picomolar affinity. Cell Rep. 2019;26(11):2916-28.e13.","journal-title":"Cell Rep"},{"issue":"4","key":"2718_CR93","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nchembio.2304","volume":"13","author":"W Qi","year":"2017","unstructured":"Qi W, Zhao K, Gu J, Huang Y, Wang Y, Zhang H, et al. An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED. Nat Chem Biol. 2017;13(4):381\u20138.","journal-title":"Nat Chem Biol"},{"issue":"1","key":"2718_CR94","doi-asserted-by":"publisher","first-page":"10165","DOI":"10.1038\/s41467-024-54500-x","volume":"15","author":"MF Mabanglo","year":"2024","unstructured":"Mabanglo MF, Wilson B, Noureldin M, Kimani SW, Mamai A, Krausser C, et al. Crystal structures of DCAF1-PROTAC-WDR5 ternary complexes provide insight into DCAF1 substrate specificity. Nat Commun. 2024;15(1):10165.","journal-title":"Nat Commun"},{"issue":"613","key":"2718_CR95","doi-asserted-by":"publisher","first-page":"eabj1578","DOI":"10.1126\/scitranslmed.abj1578","volume":"13","author":"X Yu","year":"2021","unstructured":"Yu X, Li D, Kottur J, Shen Y, Kim HS, Park KS, et al. A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models. Sci Transl Med. 2021;13(613):eabj1578.","journal-title":"Sci Transl Med."},{"issue":"1","key":"2718_CR96","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31\u201346.","journal-title":"Cancer Discov"},{"issue":"6662","key":"2718_CR97","doi-asserted-by":"publisher","first-page":"eabn4180","DOI":"10.1126\/science.abn4180","volume":"381","author":"X Lv","year":"2023","unstructured":"Lv X, Lu X, Cao J, Luo Q, Ding Y, Peng F, et al. Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors. Science. 2023;381(6662):eabn4180.","journal-title":"Science."},{"issue":"50","key":"2718_CR98","doi-asserted-by":"publisher","first-page":"25260","DOI":"10.1073\/pnas.1910391116","volume":"116","author":"LR Thomas","year":"2019","unstructured":"Thomas LR, Adams CM, Wang J, Weissmiller AM, Creighton J, Lorey SL, et al. Interaction of the oncoprotein transcription factor MYC with its chromatin cofactor WDR5 is essential for tumor maintenance. Proc Natl Acad Sci U S A. 2019;116(50):25260\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"2718_CR99","doi-asserted-by":"publisher","first-page":"e0207779","DOI":"10.1371\/journal.pone.0207779","volume":"13","author":"M Yousefelahiyeh","year":"2018","unstructured":"Yousefelahiyeh M, Xu J, Alvarado E, Yu Y, Salven D, Nissen RM. DCAF7\/WDR68 is required for normal levels of DYRK1A and DYRK1B. PLoS ONE. 2018;13(11):e0207779.","journal-title":"PLoS ONE"},{"issue":"1","key":"2718_CR100","doi-asserted-by":"publisher","first-page":"e54363","DOI":"10.1371\/journal.pone.0054363","volume":"8","author":"B Wang","year":"2013","unstructured":"Wang B, Doan D, Roman Petersen Y, Alvarado E, Alvarado G, Bhandari A, et al. Wdr68 requires nuclear access for craniofacial development. PLoS ONE. 2013;8(1):e54363.","journal-title":"PLoS ONE"},{"issue":"10","key":"2718_CR101","doi-asserted-by":"publisher","first-page":"105188","DOI":"10.1016\/j.isci.2022.105188","volume":"25","author":"S Frendo-Cumbo","year":"2022","unstructured":"Frendo-Cumbo S, Li T, Ammendolia DA, Coyaud E, Laurent EMN, Liu Y, et al. DCAF7 regulates cell proliferation through IRS1-FOXO1 signaling. iScience. 2022;25(10):105188.","journal-title":"iScience"},{"issue":"1","key":"2718_CR102","doi-asserted-by":"publisher","first-page":"e70572","DOI":"10.1002\/ctm2.70572","volume":"16","author":"R Luan","year":"2026","unstructured":"Luan R, Lin H, Zhao X, Li J, Chen M, Luo S, et al. Pan-cancer multi-omics reveals DCAF7 as an immune-modulating prognostic driver and Wnt\/\u03b2-catenin activator in hepatocellular carcinoma. Clin Transl Med. 2026;16(1):e70572.","journal-title":"Clin Transl Med"},{"issue":"1","key":"2718_CR103","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/wrna.57","volume":"2","author":"KR Phipps","year":"2011","unstructured":"Phipps KR, Charette J, Baserga SJ. The small subunit processome in ribosome biogenesis\u2014progress and prospects. Wiley Interdiscip Rev RNA. 2011;2(1):1\u201321.","journal-title":"Wiley Interdiscip Rev RNA"},{"issue":"5","key":"2718_CR104","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.cell.2006.09.045","volume":"127","author":"Y Cang","year":"2006","unstructured":"Cang Y, Zhang J, Nicholas SA, Bastien J, Li B, Zhou P, et al. Deletion of DDB1 in mouse brain and lens leads to p53-dependent elimination of proliferating cells. Cell. 2006;127(5):929\u201340.","journal-title":"Cell"},{"issue":"7","key":"2718_CR105","doi-asserted-by":"publisher","first-page":"e0134299","DOI":"10.1371\/journal.pone.0134299","volume":"10","author":"Z Hu","year":"2015","unstructured":"Hu Z, Holzschuh J, Driever W. Loss of DDB1 Leads to transcriptional p53 pathway activation in proliferating cells, cell cycle deregulation, and apoptosis in zebrafish embryos. PLoS ONE. 2015;10(7):e0134299.","journal-title":"PLoS ONE"},{"issue":"1","key":"2718_CR106","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1038\/s41598-025-30772-1","volume":"16","author":"S Jo","year":"2025","unstructured":"Jo S, Kim JS, Baek SH, Jang YK. O-GlcNAcylation of DDB1 at Ser-764 by OGT promotes cancer cell stemness in colorectal cancer through increased polyubiquitination of p53. Sci Rep. 2025;16(1):1232.","journal-title":"Sci Rep"},{"key":"2718_CR107","doi-asserted-by":"publisher","first-page":"880077","DOI":"10.3389\/fonc.2022.880077","volume":"12","author":"W Shen","year":"2022","unstructured":"Shen W, Zhou Q, Peng C, Li J, Yuan Q, Zhu H, et al. FBXW7 and the hallmarks of cancer: underlying mechanisms and prospective strategies. Front Oncol. 2022;12:880077.","journal-title":"Front Oncol"},{"issue":"1","key":"2718_CR108","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1038\/s41467-021-22319-5","volume":"12","author":"OM Khan","year":"2021","unstructured":"Khan OM, Almagro J, Nelson JK, Horswell S, Encheva V, Keyan KS, et al. Proteasomal degradation of the tumour suppressor FBW7 requires branched ubiquitylation by TRIP12. Nat Commun. 2021;12(1):2043.","journal-title":"Nat Commun"},{"issue":"9","key":"2718_CR109","doi-asserted-by":"publisher","first-page":"e70357","DOI":"10.1002\/mco2.70357","volume":"6","author":"Y Wei","year":"2025","unstructured":"Wei Y, Hankey W, Xu D, Yuan F. Programmed cell death in cancer. MedComm. 2025;6(9):e70357.","journal-title":"MedComm."},{"key":"2718_CR110","doi-asserted-by":"crossref","unstructured":"Rahman MA, Jalouli M, Al-Zharani M, Hoque Apu E, Harrath AH. Mechanistic insights into autophagy-dependent cell death (ADCD): a novel avenue for cancer therapy. Cells.\u00a02025;14(14):1072.","DOI":"10.3390\/cells14141072"},{"issue":"1","key":"2718_CR111","doi-asserted-by":"publisher","first-page":"5156","DOI":"10.1038\/s41467-020-18973-w","volume":"11","author":"M Napoli","year":"2020","unstructured":"Napoli M, Li X, Ackerman HD, Deshpande AA, Barannikov I, Pisegna MA, et al. Pan-cancer analysis reveals TAp63-regulated oncogenic lncRNAs that promote cancer progression through AKT activation. Nat Commun. 2020;11(1):5156.","journal-title":"Nat Commun"},{"issue":"8","key":"2718_CR112","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1016\/j.cub.2021.01.081","volume":"31","author":"C Ji","year":"2021","unstructured":"Ji C, Zhao H, Chen D, Zhang H, Zhao YG. \u03b2-propeller proteins WDR45 and WDR45B regulate autophagosome maturation into autolysosomes in neural cells. Curr Biol. 2021;31(8):1666-77.e6.","journal-title":"Curr Biol"},{"key":"2718_CR113","doi-asserted-by":"publisher","first-page":"15637","DOI":"10.1038\/ncomms15637","volume":"8","author":"D Bakula","year":"2017","unstructured":"Bakula D, M\u00fcller AJ, Zuleger T, Takacs Z, Franz-Wachtel M, Thost AK, et al. WIPI3 and WIPI4 \u03b2-propellers are scaffolds for LKB1-AMPK-TSC signalling circuits in the control of autophagy. Nat Commun. 2017;8:15637.","journal-title":"Nat Commun"},{"issue":"7","key":"2718_CR114","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1080\/15548627.2021.1924039","volume":"17","author":"C Ji","year":"2021","unstructured":"Ji C, Zhao YG. The BPAN and intellectual disability disease proteins WDR45 and WDR45B modulate autophagosome-lysosome fusion. Autophagy. 2021;17(7):1783\u20134.","journal-title":"Autophagy"},{"issue":"6","key":"2718_CR115","doi-asserted-by":"publisher","first-page":"e0155492","DOI":"10.1371\/journal.pone.0155492","volume":"11","author":"JM Gilmore","year":"2016","unstructured":"Gilmore JM, Sardiu ME, Groppe BD, Thornton JL, Liu X, Dayebgadoh G, et al. WDR76 Co-localizes with heterochromatin related proteins and rapidly responds to DNA damage. PLoS ONE. 2016;11(6):e0155492.","journal-title":"PLoS ONE"},{"issue":"5","key":"2718_CR116","doi-asserted-by":"publisher","first-page":"528","DOI":"10.17305\/bjbms.2020.5506","volume":"21","author":"J Yang","year":"2021","unstructured":"Yang J, Wang F, Chen B. The role of WDR76 protein in human diseases. Bosn J Basic Med Sci. 2021;21(5):528\u201334.","journal-title":"Bosn J Basic Med Sci"},{"issue":"1","key":"2718_CR117","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s12672-023-00656-9","volume":"14","author":"Y Hu","year":"2023","unstructured":"Hu Y, Tan X, Zhang L, Zhu X, Wang X. WDR76 regulates 5-fluorouracil sensitivity in colon cancer via HRAS. Discov Oncol. 2023;14(1):45.","journal-title":"Discov Oncol"},{"issue":"6","key":"2718_CR118","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1158\/0008-5472.CAN-13-3568","volume":"74","author":"Y Li","year":"2014","unstructured":"Li Y, Tergaonkar V. Noncanonical functions of telomerase: implications in telomerase-targeted cancer therapies. Cancer Res. 2014;74(6):1639\u201344.","journal-title":"Cancer Res"},{"issue":"7251","key":"2718_CR119","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/nature08137","volume":"460","author":"JI Park","year":"2009","unstructured":"Park JI, Venteicher AS, Hong JY, Choi J, Jun S, Shkreli M, et al. Telomerase modulates Wnt signalling by association with target gene chromatin. Nature. 2009;460(7251):66\u201372.","journal-title":"Nature"},{"issue":"11","key":"2718_CR120","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/s41419-024-07109-3","volume":"15","author":"X Wang","year":"2024","unstructured":"Wang X, Wang Y, Xie M, Ma S, Zhang Y, Wang L, et al. Hypermethylation of CDKN2A CpG island drives resistance to PRC2 inhibitors in SWI\/SNF loss-of-function tumors. Cell Death Dis. 2024;15(11):794.","journal-title":"Cell Death Dis"},{"issue":"6","key":"2718_CR121","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1158\/2159-8290.CD-23-0110","volume":"14","author":"Y Kazansky","year":"2024","unstructured":"Kazansky Y, Cameron D, Mueller HS, Demarest P, Zaffaroni N, Arrighetti N, et al. overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapy. Cancer Discov. 2024;14(6):965\u201381.","journal-title":"Cancer Discov"},{"issue":"1","key":"2718_CR122","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/bjc.2014.278","volume":"111","author":"J Wang","year":"2014","unstructured":"Wang J, Ou J, Guo Y, Dai T, Li X, Liu J, et al. TBLR1 is a novel prognostic marker and promotes epithelial-mesenchymal transition in cervical cancer. Br J Cancer. 2014;111(1):112\u201324.","journal-title":"Br J Cancer"},{"issue":"6088","key":"2718_CR123","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1126\/science.1218370","volume":"336","author":"K Hoffmeyer","year":"2012","unstructured":"Hoffmeyer K, Raggioli A, Rudloff S, Anton R, Hierholzer A, Del Valle I, et al. Wnt\/\u03b2-catenin signaling regulates telomerase in stem cells and cancer cells. Science. 2012;336(6088):1549\u201354.","journal-title":"Science"},{"issue":"8","key":"2718_CR124","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/nrg3286","volume":"13","author":"H Stower","year":"2012","unstructured":"Stower H. Stem cells, cancer and telomerase linked by WNT. Nat Rev Genet. 2012;13(8):521.","journal-title":"Nat Rev Genet"},{"issue":"17","key":"2718_CR125","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.4161\/cc.21790","volume":"11","author":"S Jaitner","year":"2012","unstructured":"Jaitner S, Reiche JA, Sch\u00e4ffauer AJ, Hiendlmeyer E, Herbst H, Brabletz T, et al. Human telomerase reverse transcriptase (hTERT) is a target gene of \u03b2-catenin in human colorectal tumors. Cell Cycle. 2012;11(17):3331\u20138.","journal-title":"Cell Cycle"},{"issue":"1","key":"2718_CR126","doi-asserted-by":"publisher","first-page":"e114","DOI":"10.1038\/cddis.2010.90","volume":"2","author":"S Mahmoudi","year":"2011","unstructured":"Mahmoudi S, Henriksson S, Farnebo L, Roberg K, Farnebo M. WRAP53 promotes cancer cell survival and is a potential target for cancer therapy. Cell Death Dis. 2011;2(1):e114.","journal-title":"Cell Death Dis"},{"key":"2718_CR127","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3389\/fgene.2015.00091","volume":"6","author":"S Henriksson","year":"2015","unstructured":"Henriksson S, Farnebo M. On the road with WRAP53\u03b2: guardian of Cajal bodies and genome integrity. Front Genet. 2015;6:91.","journal-title":"Front Genet"},{"key":"2718_CR128","doi-asserted-by":"crossref","unstructured":"Lin MY, Jiang D, Tian N, Yao X, Pan XH, Ma LH, et al. TCAB1: a key promoter of tumor growth through telomere maintenance and senescence evasion. Cell Cycle. 2026;25(1):1\u201314.","DOI":"10.1080\/15384101.2025.2609646"},{"issue":"2","key":"2718_CR129","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/s41594-024-01452-x","volume":"32","author":"T Cookis","year":"2025","unstructured":"Cookis T, Lydecker A, Sauer P, Kasinath V, Nogales E. Structural basis for the inhibition of PRC2 by active transcription histone posttranslational modifications. Nat Struct Mol Biol. 2025;32(2):393\u2013404.","journal-title":"Nat Struct Mol Biol"},{"key":"2718_CR130","doi-asserted-by":"crossref","unstructured":"Bhat MY, Liu X. Emerging structural insights into PRC2 function in development and disease. Trends Biochem Sci. 2026;51(2):172\u201386.","DOI":"10.1016\/j.tibs.2025.11.003"},{"issue":"1","key":"2718_CR131","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.gendis.2023.02.039","volume":"11","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Xing C, Deng Y, Ye C, Peng H. HIF-1\u03b1 signaling: essential roles in tumorigenesis and implications in targeted therapies. Genes Dis. 2024;11(1):234\u201351.","journal-title":"Genes Dis"},{"issue":"1","key":"2718_CR132","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","volume":"8","author":"Z Chen","year":"2023","unstructured":"Chen Z, Han F, Du Y, Shi H, Zhou W. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2023;8(1):70.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2718_CR133","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s11658-024-00682-7","volume":"30","author":"J Zhang","year":"2025","unstructured":"Zhang J, Yao M, Xia S, Zeng F, Liu Q. Systematic and comprehensive insights into HIF-1 stabilization under normoxic conditions: implications for cellular adaptation and therapeutic strategies in cancer. Cell Mol Biol Lett. 2025;30(1):2.","journal-title":"Cell Mol Biol Lett"},{"key":"2718_CR134","doi-asserted-by":"publisher","first-page":"118023","DOI":"10.1016\/j.biopha.2025.118023","volume":"186","author":"H Mahaki","year":"2025","unstructured":"Mahaki H, Nobari S, Tanzadehpanah H, Babaeizad A, Kazemzadeh G, Mehrabzadeh M, et al. Targeting VEGF signaling for tumor microenvironment remodeling and metastasis inhibition: Therapeutic strategies and insights. Biomed Pharmacother. 2025;186:118023.","journal-title":"Biomed Pharmacother"},{"key":"2718_CR135","doi-asserted-by":"crossref","unstructured":"Magar AG, Morya VK, Kwak MK, Oh JU, Noh KC. A molecular perspective on HIF-1\u03b1 and angiogenic stimulator networks and their role in solid tumors: an update. Int J Mol Sci. 2024;25(6):3313.","DOI":"10.3390\/ijms25063313"},{"issue":"6","key":"2718_CR136","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1016\/j.ymthe.2021.02.017","volume":"29","author":"T Chen","year":"2021","unstructured":"Chen T, Li K, Liu Z, Liu J, Wang Y, Sun R, et al. WDR5 facilitates EMT and metastasis of CCA by increasing HIF-1\u03b1 accumulation in Myc-dependent and independent pathways. Mol Ther. 2021;29(6):2134\u201350.","journal-title":"Mol Ther"},{"key":"2718_CR137","doi-asserted-by":"crossref","unstructured":"Shaikat AH, Azad SMAK, Tamim MAR, Ullah MS, Amin MN, Sabbir MK, et al. Investigating hypoxia-inducible factor signaling in cancer: mechanisms, clinical implications, targeted therapeutic strategies, and resistance. Cancer Pathog Ther. 2025;4(3):174\u201391.","DOI":"10.1016\/j.cpt.2025.07.003"},{"issue":"18","key":"2718_CR138","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.7150\/thno.27310","volume":"8","author":"Z Tan","year":"2018","unstructured":"Tan Z, Chen K, Wu W, Zhou Y, Zhu J, Wu G, et al. Overexpression of HOXC10 promotes angiogenesis in human glioma via interaction with PRMT5 and upregulation of VEGFA expression. Theranostics. 2018;8(18):5143\u201358.","journal-title":"Theranostics"},{"issue":"1","key":"2718_CR139","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1136\/gutjnl-2013-306388","volume":"64","author":"L Liu","year":"2015","unstructured":"Liu L, Lin C, Liang W, Wu S, Liu A, Wu J, et al. TBL1XR1 promotes lymphangiogenesis and lymphatic metastasis in esophageal squamous cell carcinoma. Gut. 2015;64(1):26\u201336.","journal-title":"Gut"},{"issue":"3","key":"2718_CR140","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1620\/tjem.241.239","volume":"241","author":"M Ma","year":"2017","unstructured":"Ma M, Yu N. Over-expression of TBL1XR1 indicates poor prognosis of serous epithelial ovarian cancer. Tohoku J Exp Med. 2017;241(3):239\u201347.","journal-title":"Tohoku J Exp Med"},{"issue":"9","key":"2718_CR141","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1111\/jgh.13749","volume":"32","author":"H Liu","year":"2017","unstructured":"Liu H, Liu Z, Li K, Li S, Song L, Gong Z, et al. TBL1XR1 predicts isolated tumor cells and micrometastasis in patients with TNM stage I\/II colorectal cancer. J Gastroenterol Hepatol. 2017;32(9):1570\u201380.","journal-title":"J Gastroenterol Hepatol"},{"issue":"11","key":"2718_CR142","doi-asserted-by":"publisher","first-page":"9097","DOI":"10.1074\/jbc.M110.165605","volume":"286","author":"F Wang","year":"2011","unstructured":"Wang F, Yamauchi M, Muramatsu M, Osawa T, Tsuchida R, Shibuya M. RACK1 regulates VEGF\/Flt1-mediated cell migration via activation of a PI3K\/Akt pathway. J Biol Chem. 2011;286(11):9097\u2013106.","journal-title":"J Biol Chem"},{"issue":"2","key":"2718_CR143","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.molcel.2007.01.001","volume":"25","author":"YV Liu","year":"2007","unstructured":"Liu YV, Baek JH, Zhang H, Diez R, Cole RN, Semenza GL. RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alpha. Mol Cell. 2007;25(2):207\u201317.","journal-title":"Mol Cell"},{"issue":"9","key":"2718_CR144","doi-asserted-by":"publisher","first-page":"4673","DOI":"10.1016\/j.apsb.2025.07.019","volume":"15","author":"X Li","year":"2025","unstructured":"Li X, Shen X, Mao X, Wang Y, Dong Y, Sun S, et al. PARylation promotes acute kidney injury via RACK1 dimerization-mediated HIF-1\u03b1 degradation. Acta Pharm Sin B. 2025;15(9):4673\u201391.","journal-title":"Acta Pharm Sin B"},{"issue":"14","key":"2718_CR145","doi-asserted-by":"publisher","first-page":"6081","DOI":"10.7150\/ijbs.115401","volume":"21","author":"S Xiao","year":"2025","unstructured":"Xiao S, Tian L, Gan X, Xu X, Liao M, Song D, et al. Role of Ubiquitin-regulated EMT in cancer metastasis and chemoresistance. Int J Biol Sci. 2025;21(14):6081\u2013112.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"2718_CR146","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1186\/s12964-025-02445-z","volume":"23","author":"J Cheng","year":"2025","unstructured":"Cheng J, Liu O, Bin X, Tang Z. F-box proteins in cancer: from cancer cells to the tumor microenvironment. Cell Commun Signal. 2025;23(1):433.","journal-title":"Cell Commun Signal"},{"key":"2718_CR147","doi-asserted-by":"publisher","first-page":"216058","DOI":"10.1016\/j.canlet.2023.216058","volume":"556","author":"X Wei","year":"2023","unstructured":"Wei X, Wang B, Wu Z, Yang X, Guo Y, Yang Y, et al. WD repeat protein 54-mediator of ErbB2-driven cell motility 1 axis promotes bladder cancer tumorigenesis and metastasis and impairs chemosensitivity. Cancer Lett. 2023;556:216058.","journal-title":"Cancer Lett"},{"issue":"7","key":"2718_CR148","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1002\/ijc.31736","volume":"144","author":"Y Yuan","year":"2019","unstructured":"Yuan Y, Qi G, Shen H, Guo A, Cao F, Zhu Y, et al. Clinical significance and biological function of WD repeat domain 54 as an oncogene in colorectal cancer. Int J Cancer. 2019;144(7):1584\u201395.","journal-title":"Int J Cancer"},{"issue":"2","key":"2718_CR149","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.bbamcr.2018.11.009","volume":"1866","author":"A Maeda","year":"2019","unstructured":"Maeda A, Nishino T, Matsunaga R, Yokoyama A, Suga H, Yagi T, et al. Transglutaminase-mediated cross-linking of WDR54 regulates EGF receptor-signaling. Biochim Biophys Acta Mol Cell Res. 2019;1866(2):285\u201395.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"issue":"1","key":"2718_CR150","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00018-024-05446-2","volume":"81","author":"ZY Tang","year":"2024","unstructured":"Tang ZY, Wang XM, Xu CW, Sun QQ, Hua YX, Zhou QY, et al. DCAF13 promotes ovarian cancer progression by activating FRAS1-mediated FAK signaling pathway. Cell Mol Life Sci. 2024;81(1):421.","journal-title":"Cell Mol Life Sci"},{"issue":"10","key":"2718_CR151","doi-asserted-by":"publisher","first-page":"110656","DOI":"10.1016\/j.jbc.2025.110656","volume":"301","author":"XM Wang","year":"2025","unstructured":"Wang XM, Lv MD, Wu ZJ, Wu XH, Sun GY, Wu ZH, et al. Nucleolar protein DCAF13 promotes non-small cell lung cancer cell proliferation via facilitating rDNA transcription and ribosome biogenesis. J Biol Chem. 2025;301(10):110656.","journal-title":"J Biol Chem"},{"issue":"3","key":"2718_CR152","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1080\/15384101.2021.1874695","volume":"20","author":"D Han","year":"2021","unstructured":"Han D, Wang L, Chen B, Zhao W, Liang Y, Li Y, et al. USP1-WDR48 deubiquitinase complex enhances TGF-\u03b2 induced epithelial-mesenchymal transition of TNBC cells via stabilizing TAK1. Cell Cycle. 2021;20(3):320\u201331.","journal-title":"Cell Cycle"},{"issue":"23","key":"2718_CR153","doi-asserted-by":"publisher","first-page":"5755","DOI":"10.1111\/jcmm.17583","volume":"26","author":"B Li","year":"2022","unstructured":"Li B, Zhang YW, Cao K, Li C, Chen Q, Jiang YH, et al. WD repeat domain 48 promotes hepatocellular carcinoma progression by stabilizing c-Myc. J Cell Mol Med. 2022;26(23):5755\u201366.","journal-title":"J Cell Mol Med"},{"issue":"3","key":"2718_CR154","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1080\/17568919.2025.2453414","volume":"17","author":"X Hu","year":"2025","unstructured":"Hu X, Wu Y, Yao M, Chen Z, Li Q. The other side of the coin: protein deubiquitination by ubiquitin-specific protease 1 in cancer progression and therapy. Future Med Chem. 2025;17(3):329\u201345.","journal-title":"Future Med Chem"},{"key":"2718_CR155","doi-asserted-by":"publisher","first-page":"115396","DOI":"10.1016\/j.ejca.2025.115396","volume":"220","author":"J Neo","year":"2025","unstructured":"Neo J, Ong EHW, Zhang X, Chow WM, Wee JTS, Fong KW, et al. Plasma Epstein-Barr virus DNA for disease surveillance in endemic nasopharyngeal carcinoma: analysis of a real-world database. Eur J Cancer. 2025;220:115396.","journal-title":"Eur J Cancer"},{"issue":"6","key":"2718_CR156","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1056\/NEJMoa1701717","volume":"377","author":"KCA Chan","year":"2017","unstructured":"Chan KCA, Woo JKS, King A, Zee BCY, Lam WKJ, Chan SL, et al. Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer. N Engl J Med. 2017;377(6):513\u201322.","journal-title":"N Engl J Med"},{"issue":"8","key":"2718_CR157","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.annonc.2022.04.068","volume":"33","author":"DCT Chan","year":"2022","unstructured":"Chan DCT, Lam WKJ, Hui EP, Ma BBY, Chan CML, Lee VCT, et al. Improved risk stratification of nasopharyngeal cancer by targeted sequencing of Epstein-Barr virus DNA in post-treatment plasma. Ann Oncol. 2022;33(8):794\u2013803.","journal-title":"Ann Oncol"},{"issue":"1","key":"2718_CR158","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1186\/s12885-024-12259-w","volume":"24","author":"Y Chen","year":"2024","unstructured":"Chen Y, Huang Y, Chen X, Chen Z, Peng X, Lin S, et al. Efficacy of salvage surgery versus re-irradiation for isolated regional lymph node recurrence in patients with nasopharyngeal carcinoma. BMC Cancer. 2024;24(1):483.","journal-title":"BMC Cancer"},{"issue":"8","key":"2718_CR159","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/S1470-2045(21)00302-8","volume":"22","author":"Y Yang","year":"2021","unstructured":"Yang Y, Qu S, Li J, Hu C, Xu M, Li W, et al. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2021;22(8):1162\u201374.","journal-title":"Lancet Oncol"},{"issue":"20","key":"2718_CR160","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1001\/jama.2023.20181","volume":"330","author":"HQ Mai","year":"2023","unstructured":"Mai HQ, Chen QY, Chen D, Hu C, Yang K, Wen J, et al. Toripalimab Plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: The JUPITER-02 randomized clinical trial. JAMA. 2023;330(20):1961\u201370.","journal-title":"JAMA"},{"issue":"36","key":"2718_CR161","doi-asserted-by":"publisher","first-page":"e2403262","DOI":"10.1002\/advs.202403262","volume":"11","author":"QJ Li","year":"2024","unstructured":"Li QJ, Fang XL, Li YQ, Lin JY, Huang CL, He SW, et al. DCAF7 acts as a scaffold to recruit USP10 for G3BP1 Deubiquitylation and facilitates chemoresistance and metastasis in nasopharyngeal carcinoma. Adv Sci (Weinh). 2024;11(36):e2403262.","journal-title":"Adv Sci (Weinh)"},{"key":"2718_CR162","doi-asserted-by":"publisher","first-page":"119840","DOI":"10.1016\/j.lfs.2021.119840","volume":"283","author":"P Zhang","year":"2021","unstructured":"Zhang P, Shao Y, Quan F, Liu L, Yang J. FBP1 enhances the radiosensitivity by suppressing glycolysis via the FBXW7\/mTOR axis in nasopharyngeal carcinoma cells. Life Sci. 2021;283:119840.","journal-title":"Life Sci"},{"issue":"1","key":"2718_CR163","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/2211-5463.13519","volume":"13","author":"JY Wu","year":"2023","unstructured":"Wu JY, Niu YT, Huang SN, Tan YM, Yang ZD, Fang YY, et al. WDHD1 is over-expressed in nasopharyngeal carcinoma and may control the expression of ITGAV. FEBS Open Bio. 2023;13(1):102\u201317.","journal-title":"FEBS Open Bio"},{"issue":"5","key":"2718_CR164","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1089\/hum.2016.136","volume":"28","author":"J Wu","year":"2017","unstructured":"Wu J, Tan X, Lin J, Yuan L, Chen J, Qiu L, et al. Minicircle-oriP-miR-31 as a Novel EBNA1-Specific miRNA therapy approach for nasopharyngeal carcinoma. Hum Gene Ther. 2017;28(5):415\u201327.","journal-title":"Hum Gene Ther"},{"issue":"1","key":"2718_CR165","doi-asserted-by":"publisher","first-page":"e2211297120","DOI":"10.1073\/pnas.2211297120","volume":"120","author":"KB Teuscher","year":"2023","unstructured":"Teuscher KB, Chowdhury S, Meyers KM, Tian J, Sai J, Van Meveren M, et al. Structure-based discovery of potent WD repeat domain 5 inhibitors that demonstrate efficacy and safety in preclinical animal models. Proc Natl Acad Sci U S A. 2023;120(1):e2211297120.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"17","key":"2718_CR166","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.2217\/bmm-2021-0184","volume":"15","author":"A Ji","year":"2021","unstructured":"Ji A, Qian L, Tian Z, Cui J. WDR5 promotes the proliferation of lung adenocarcinoma by inducing SOX9 expression. Biomark Med. 2021;15(17):1599\u2013609.","journal-title":"Biomark Med"},{"issue":"15","key":"2718_CR167","doi-asserted-by":"publisher","first-page":"e70090","DOI":"10.1002\/cam4.70090","volume":"13","author":"Y Zhan","year":"2024","unstructured":"Zhan Y, Zhang Z, Yin A, Su X, Tang N, Chen Y, et al. RBBP4: A novel diagnostic and prognostic biomarker for non-small-cell lung cancer correlated with autophagic cell death. Cancer Med. 2024;13(15):e70090.","journal-title":"Cancer Med"},{"issue":"21","key":"2718_CR168","doi-asserted-by":"publisher","first-page":"5587","DOI":"10.1158\/0008-5472.CAN-19-0428","volume":"79","author":"H Dong","year":"2019","unstructured":"Dong H, Liu S, Zhang X, Chen S, Kang L, Chen Y, et al. An allosteric PRC2 inhibitor targeting EED suppresses tumor progression by modulating the immune response. Cancer Res. 2019;79(21):5587\u201396.","journal-title":"Cancer Res"},{"issue":"6","key":"2718_CR169","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/1878-0261.12200","volume":"12","author":"Y Xiao","year":"2018","unstructured":"Xiao Y, Yin C, Wang Y, Lv H, Wang W, Huang Y, et al. FBXW7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy. Mol Oncol. 2018;12(6):883\u201395.","journal-title":"Mol Oncol"},{"issue":"9","key":"2718_CR170","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.7150\/ijbs.23845","volume":"14","author":"B Yuan","year":"2018","unstructured":"Yuan B, Zhang R, Hu J, Liu Z, Yang C, Zhang T, et al. WDR1 promotes cell growth and migration and contributes to malignant phenotypes of non-small cell lung cancer through ADF\/cofilin-mediated actin dynamics. Int J Biol Sci. 2018;14(9):1067\u201380.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"2718_CR171","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41598-024-83337-z","volume":"15","author":"D Hu","year":"2025","unstructured":"Hu D, Th\u00e9riault BL, Talebian V, Hoffer L, Owen J, Lim J, et al. CDC40 suppression induces CDCA5 splicing defects and anti-proliferative effects in lung cancer cells. Sci Rep. 2025;15(1):315.","journal-title":"Sci Rep"},{"issue":"9","key":"2718_CR172","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.681","volume":"10","author":"M Lv","year":"2022","unstructured":"Lv M. WD repeat domain 6 as a novelty prognostic biomarker correlates with immune infiltration in lung cancer: a preliminary study. Immun Inflamm Dis. 2022;10(9):e681.","journal-title":"Immun Inflamm Dis"},{"issue":"1","key":"2718_CR173","first-page":"50","volume":"74","author":"AMD Wolf","year":"2024","unstructured":"Wolf AMD, Oeffinger KC, Shih TY, Walter LC, Church TR, Fontham ETH, et al. Screening for lung cancer: 2023 guideline update from the American Cancer Society. CA Cancer J Clin. 2024;74(1):50\u201381.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"2718_CR174","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41416-024-02709-4","volume":"131","author":"U Malapelle","year":"2024","unstructured":"Malapelle U, Leighl N, Addeo A, Hershkovitz D, Hochmair MJ, Khorshid O, et al. Recommendations for reporting tissue and circulating tumour (ct)DNA next-generation sequencing results in non-small cell lung cancer. Br J Cancer. 2024;131(2):212\u20139.","journal-title":"Br J Cancer"},{"issue":"10","key":"2718_CR175","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.jtho.2024.06.010","volume":"19","author":"JD Spicer","year":"2024","unstructured":"Spicer JD, Cascone T, Wynes MW, Ahn MJ, Dacic S, Felip E, et al. Neoadjuvant and adjuvant treatments for early stage resectable NSCLC: consensus recommendations from the international association for the study of lung cancer. J Thorac Oncol. 2024;19(10):1373\u2013414.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"2718_CR176","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/s41467-023-35962-x","volume":"14","author":"J Chmielecki","year":"2023","unstructured":"Chmielecki J, Mok T, Wu YL, Han JY, Ahn MJ, Ramalingam SS, et al. Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial. Nat Commun. 2023;14(1):1071.","journal-title":"Nat Commun"},{"key":"2718_CR177","doi-asserted-by":"publisher","first-page":"103482","DOI":"10.1016\/j.eclinm.2025.103482","volume":"88","author":"S Oresti","year":"2025","unstructured":"Oresti S, Salomone F, Nuccio A, Ogliari FR, Riva ST, Mollica L, et al. Impact of platinum-based chemotherapy and CTLA-4 inhibition on acquired resistance to first-line anti-PD-1\/PD-L1 agents in non-small cell lung cancer: a systematic review and reconstructed individual patient data analysis. EClinicalMedicine. 2025;88:103482.","journal-title":"EClinicalMedicine"},{"key":"2718_CR178","doi-asserted-by":"publisher","first-page":"1489977","DOI":"10.3389\/fonc.2024.1489977","volume":"14","author":"C Rother","year":"2024","unstructured":"Rother C, John T, Wong A. Biomarkers for immunotherapy resistance in non-small cell lung cancer. Front Oncol. 2024;14:1489977.","journal-title":"Front Oncol"},{"issue":"4","key":"2718_CR179","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.4251\/wjgo.v16.i4.1180","volume":"16","author":"HT Qu","year":"2024","unstructured":"Qu HT, Li Q, Hao L, Ni YJ, Luan WY, Yang Z, et al. Esophageal cancer screening, early detection and treatment: Current insights and future directions. World J Gastrointest Oncol. 2024;16(4):1180\u201391.","journal-title":"World J Gastrointest Oncol"},{"issue":"4","key":"2718_CR180","doi-asserted-by":"publisher","first-page":"393","DOI":"10.6004\/jnccn.2023.0019","volume":"21","author":"JA Ajani","year":"2023","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, Cooke D, Corvera C, Das P, et al. Esophageal and Esophagogastric junction cancers, version 2.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023;21(4):393\u2013422.","journal-title":"J Natl Compr Canc Netw."},{"issue":"1","key":"2718_CR181","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s44276-025-00158-x","volume":"3","author":"Q Hu","year":"2025","unstructured":"Hu Q, Kimura Y, Ikeda S, Tanaka Y, Nakanoko T, Ota M, et al. Circulating tumor DNA monitoring detects minimal residual disease and predicts outcomes in patients with esophageal adenocarcinoma or squamous cell carcinoma after esophagectomy. BJC Rep. 2025;3(1):52.","journal-title":"BJC Rep"},{"issue":"6","key":"2718_CR182","doi-asserted-by":"publisher","first-page":"106707","DOI":"10.4251\/wjgo.v17.i6.106707","volume":"17","author":"G Massaro","year":"2025","unstructured":"Massaro G, Paulet A, Lavacchi D, Brugia M, Rossini D, Giommoni E, et al. Immune checkpoint inhibitors in the first-line treatment of esophageal squamous cell carcinoma: Minireview for a big shift. World J Gastrointest Oncol. 2025;17(6):106707.","journal-title":"World J Gastrointest Oncol"},{"issue":"1","key":"2718_CR183","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13046-023-02630-3","volume":"42","author":"Y Pan","year":"2023","unstructured":"Pan Y, Liu J, Gao Y, Guo Y, Wang C, Liang Z, et al. FBXW7 loss of function promotes esophageal squamous cell carcinoma progression via elevating MAP4 and ERK phosphorylation. J Exp Clin Cancer Res. 2023;42(1):75.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"2718_CR184","doi-asserted-by":"publisher","first-page":"20186","DOI":"10.1038\/s41598-022-24743-z","volume":"12","author":"L Chen","year":"2022","unstructured":"Chen L, Lu J, Xu T, Yan Z, Guo Y, Dong Z, et al. KTN1-AS1, a SOX2-mediated lncRNA, activates epithelial-mesenchymal transition process in esophageal squamous cell carcinoma. Sci Rep. 2022;12(1):20186.","journal-title":"Sci Rep"},{"issue":"6","key":"2718_CR185","first-page":"7204","volume":"16","author":"N Yu","year":"2018","unstructured":"Yu N, Zhang P, Wang L, He X, Yang S, Lu H. RBBP7 is a prognostic biomarker in patients with esophageal squamous cell carcinoma. Oncol Lett. 2018;16(6):7204\u201311.","journal-title":"Oncol Lett"},{"key":"2718_CR186","doi-asserted-by":"crossref","unstructured":"Liang H, Fisher ML, Wu C, Ballon C, Sun X, Mills AA. PRMT5\/WDR77 enhances the proliferation of squamous cell carcinoma via the \u0394Np63\u03b1-p21 axis. Cancers (Basel). 2024;16(22):3789.","DOI":"10.3390\/cancers16223789"},{"key":"2718_CR187","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/1471-2407-13-137","volume":"13","author":"Q Wang","year":"2013","unstructured":"Wang Q, Ma C, Kemmner W. Wdr66 is a novel marker for risk stratification and involved in epithelial-mesenchymal transition of esophageal squamous cell carcinoma. BMC Cancer. 2013;13:137.","journal-title":"BMC Cancer"},{"issue":"4","key":"2718_CR188","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1080\/15384047.2015.1016687","volume":"16","author":"N Wang","year":"2015","unstructured":"Wang N, Liu F, Cao F, Jia Y, Wang J, Ma W, et al. RACK1 predicts poor prognosis and regulates progression of esophageal squamous cell carcinoma through its epithelial-mesenchymal transition. Cancer Biol Ther. 2015;16(4):528\u201340.","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"2718_CR189","doi-asserted-by":"publisher","first-page":"e91670","DOI":"10.1371\/journal.pone.0091670","volume":"9","author":"X Rao","year":"2014","unstructured":"Rao X, Huang D, Sui X, Liu G, Song X, Xie J, et al. Overexpression of WRAP53 is associated with development and progression of esophageal squamous cell carcinoma. PLoS ONE. 2014;9(3):e91670.","journal-title":"PLoS ONE"},{"issue":"1","key":"2718_CR190","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/cas.16381","volume":"116","author":"P Zhang","year":"2025","unstructured":"Zhang P, Xiang H, Peng Q, Ma L, Weng C, Liu G, et al. METTL14 attenuates cancer stemness by suppressing ATF5\/WDR74\/\u03b2-catenin axis in gastric cancer. Cancer Sci. 2025;116(1):112\u201327.","journal-title":"Cancer Sci"},{"issue":"3","key":"2718_CR191","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s10620-023-08208-5","volume":"69","author":"H Ding","year":"2024","unstructured":"Ding H, Feng Z, Hu K. GRWD1 over-expression promotes gastric cancer progression by activating notch signaling pathway via up-regulation of ADAM17. Dig Dis Sci. 2024;69(3):821\u201334.","journal-title":"Dig Dis Sci"},{"issue":"2","key":"2718_CR192","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s11596-021-2345-y","volume":"41","author":"YP Yang","year":"2021","unstructured":"Yang YP, Qin RH, Zhao JJ, Qin XY. BOP1 silencing suppresses gastric cancer proliferation through p53 modulation. Curr Med Sci. 2021;41(2):287\u201396.","journal-title":"Curr Med Sci"},{"issue":"1","key":"2718_CR193","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/s41420-025-02643-1","volume":"11","author":"S Lin","year":"2025","unstructured":"Lin S, Kong W, Liu X, Yin G, Cheng K, Mao Z, et al. FOXP2 suppresses gastric cancer progression by transcriptionally repressing FBXW2 via WASL degradation. Cell Death Discov. 2025;11(1):348.","journal-title":"Cell Death Discov"},{"issue":"17","key":"2718_CR194","doi-asserted-by":"publisher","first-page":"3752","DOI":"10.1016\/j.ejca.2013.07.015","volume":"49","author":"S Zeng","year":"2013","unstructured":"Zeng S, Tao Y, Huang J, Zhang S, Shen L, Yang H, et al. WD40 repeat-containing 62 overexpression as a novel indicator of poor prognosis for human gastric cancer. Eur J Cancer. 2013;49(17):3752\u201362.","journal-title":"Eur J Cancer"},{"issue":"1","key":"2718_CR195","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41467-018-08230-6","volume":"10","author":"WJ Jeong","year":"2019","unstructured":"Jeong WJ, Park JC, Kim WS, Ro EJ, Jeon SH, Lee SK, et al. WDR76 is a RAS binding protein that functions as a tumor suppressor via RAS degradation. Nat Commun. 2019;10(1):295.","journal-title":"Nat Commun"},{"issue":"9","key":"2718_CR196","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1007\/s10620-019-05583-w","volume":"64","author":"X Luo","year":"2019","unstructured":"Luo X, Liu Y, Ma S, Liu L, Xie R, Wang S. WDR34 activates Wnt\/Beta-catenin signaling in hepatocellular carcinoma. Dig Dis Sci. 2019;64(9):2591\u20139.","journal-title":"Dig Dis Sci"},{"key":"2718_CR197","doi-asserted-by":"publisher","first-page":"117955492513489","DOI":"10.1177\/11795549251348902","volume":"19","author":"R Zhang","year":"2025","unstructured":"Zhang R, Liu D, Feng X, Yang Z, Zhang K. WD40 protein NLE1 as a novel diagnostic biomarker promoting hepatocellular carcinoma proliferation. Clin Med Insights Oncol. 2025;19:11795549251348902.","journal-title":"Clin Med Insights Oncol"},{"key":"2718_CR198","doi-asserted-by":"crossref","unstructured":"Kim DJ, Yi YW, Seong YS. Beta-transducin repeats-containing proteins as an anticancer target. Cancers (Basel).\u00a02023;15(17):4248.","DOI":"10.3390\/cancers15174248"},{"issue":"Pt 2","key":"2718_CR199","doi-asserted-by":"publisher","first-page":"148692","DOI":"10.1016\/j.ijbiomac.2025.148692","volume":"333","author":"XZ Pan","year":"2025","unstructured":"Pan XZ, Tang K, Ren LK, Chen SJ, Chen S, Li SY, et al. DTL promotes pancreatic cancer progression through ubiquitin-mediated degradation of SMAD4. Int J Biol Macromol. 2025;333(Pt 2):148692.","journal-title":"Int J Biol Macromol"},{"key":"2718_CR200","doi-asserted-by":"crossref","unstructured":"Zhang Y, Lei Y, Xu J, Hua J, Zhang B, Liu J, et al. Role of damage DNA-binding protein 1 in pancreatic cancer progression and chemoresistance. Cancers (Basel).\u00a02019;11(12):1998.","DOI":"10.3390\/cancers11121998"},{"issue":"1","key":"2718_CR201","doi-asserted-by":"publisher","first-page":"20220624","DOI":"10.1515\/med-2022-0624","volume":"18","author":"W Yin","year":"2023","unstructured":"Yin W, Song X, Xiang Y. WDR79 promotes aerobic glycolysis of pancreatic ductal adenocarcinoma (PDAC) by the suppression of SIRT4. Open Med (Wars). 2023;18(1):20220624.","journal-title":"Open Med (Wars)"},{"key":"2718_CR202","doi-asserted-by":"crossref","unstructured":"Guillon C, Pichereaux C, Lazar I, Chaoui K, Mouton-Barbosa E, Liauzun M, et al. Mass spectrometry-based workflow for the identification and quantification of alternative and canonical proteins in pancreatic cancer cells. Cells. 2024;13(23):1966.","DOI":"10.3390\/cells13231966"},{"issue":"31","key":"2718_CR203","doi-asserted-by":"publisher","first-page":"e39153","DOI":"10.1097\/MD.0000000000039153","volume":"103","author":"X Yang","year":"2024","unstructured":"Yang X, Luo T, Liu Z, Liu J, Yang Z. WD repeat domain 43 as a new predictive indicator and its connection with tumor immune cell infiltration in pan-cancer. Medicine (Baltimore). 2024;103(31):e39153.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"2718_CR204","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1186\/s12935-021-02109-1","volume":"21","author":"Z Li","year":"2021","unstructured":"Li Z, Feng M, Zhang J, Wang X, Xu E, Wang C, et al. WD40 repeat 43 mediates cell survival, proliferation, migration and invasion via vimentin in colorectal cancer. Cancer Cell Int. 2021;21(1):418.","journal-title":"Cancer Cell Int"},{"issue":"12","key":"2718_CR205","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.1007\/s11010-024-04937-x","volume":"479","author":"S Wen","year":"2024","unstructured":"Wen S, Huang X, Xiong L, Zeng H, Wu S, An K, et al. WDR12\/RAC1 axis promoted proliferation and anti-apoptosis in colorectal cancer cells. Mol Cell Biochem. 2024;479(12):3341\u201354.","journal-title":"Mol Cell Biochem"},{"key":"2718_CR206","doi-asserted-by":"publisher","first-page":"44275","DOI":"10.1038\/srep44275","volume":"7","author":"H Liu","year":"2017","unstructured":"Liu H, Xu Y, Zhang Q, Li K, Wang D, Li S, et al. Correlations between TBL1XR1 and recurrence of colorectal cancer. Sci Rep. 2017;7:44275.","journal-title":"Sci Rep"},{"issue":"8","key":"2718_CR207","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/s41417-023-00624-z","volume":"30","author":"L Guo","year":"2023","unstructured":"Guo L, Xia Y, Li H, Wang Z, Xu H, Dai X, et al. FIT links c-Myc and P53 acetylation by recruiting RBBP7 during colorectal carcinogenesis. Cancer Gene Ther. 2023;30(8):1124\u201333.","journal-title":"Cancer Gene Ther"},{"issue":"6","key":"2718_CR208","doi-asserted-by":"publisher","first-page":"14450","DOI":"10.1080\/21655979.2022.2086381","volume":"13","author":"J Cai","year":"2022","unstructured":"Cai J, Su L, Luo W. WD repeat domain 62 (WDR62) promotes resistance of colorectal cancer to oxaliplatin through modulating mitogen-activated protein kinase (MAPK) signaling. Bioengineered. 2022;13(6):14450\u20139.","journal-title":"Bioengineered"},{"key":"2718_CR209","doi-asserted-by":"publisher","first-page":"5625026","DOI":"10.1155\/2019\/5625026","volume":"2019","author":"XY Li","year":"2019","unstructured":"Li XY, Hu Y, Li NS, Wan JH, Zhu Y, Lu NH. RACK1 acts as a potential tumor promoter in colorectal cancer. Gastroenterol Res Pract. 2019;2019:5625026.","journal-title":"Gastroenterol Res Pract"},{"key":"2718_CR210","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/1471-2407-12-294","volume":"12","author":"H Zhang","year":"2012","unstructured":"Zhang H, Wang DW, Adell G, Sun XF. WRAP53 is an independent prognostic factor in rectal cancer- a study of Swedish clinical trial of preoperative radiotherapy in rectal cancer patients. BMC Cancer. 2012;12:294.","journal-title":"BMC Cancer"},{"issue":"2","key":"2718_CR211","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1053\/j.gastro.2024.11.001","volume":"168","author":"SC Shah","year":"2025","unstructured":"Shah SC, Wang AY, Wallace MB, Hwang JH. AGA clinical practice update on screening and surveillance in individuals at increased risk for gastric cancer in the United States: expert review. Gastroenterology. 2025;168(2):405-16.e1.","journal-title":"Gastroenterology"},{"issue":"5","key":"2718_CR212","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1055\/a-2529-5025","volume":"57","author":"M Dinis-Ribeiro","year":"2025","unstructured":"Dinis-Ribeiro M, Lib\u00e2nio D, Uchima H, Spaander MCW, Bornschein J, Matysiak-Budnik T, et al. Management of epithelial precancerous conditions and early neoplasia of the stomach (MAPS III): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG) and European Society of Pathology (ESP) Guideline update 2025. Endoscopy. 2025;57(5):504\u201354.","journal-title":"Endoscopy"},{"key":"2718_CR213","doi-asserted-by":"crossref","unstructured":"Sahwan O, Batha L, Jamal F, Sonbol MB. Circulating tumor DNA (ctDNA) in gastroesophageal adenocarcinoma (GEA): evidence and emerging applications. Cancers (Basel).\u00a02025;17(22):3692.","DOI":"10.3390\/cancers17223692"},{"key":"2718_CR214","doi-asserted-by":"publisher","first-page":"103038","DOI":"10.1016\/j.ctrv.2025.103038","volume":"141","author":"C Migliore","year":"2025","unstructured":"Migliore C, Fenocchio E, Giordano S, Corso S. Precision oncology in gastric cancer: shaping the future of personalized treatment. Cancer Treat Rev. 2025;141:103038.","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"2718_CR215","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","volume":"78","author":"AG Singal","year":"2023","unstructured":"Singal AG, Llovet JM, Yarchoan M, Mehta N, Heimbach JK, Dawson LA, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78(6):1922\u201365.","journal-title":"Hepatology"},{"issue":"2","key":"2718_CR216","doi-asserted-by":"publisher","first-page":"101666","DOI":"10.1016\/j.jhepr.2025.101666","volume":"8","author":"GN Ioannou","year":"2026","unstructured":"Ioannou GN, Taddei TH, Planeta BM, Huang GD, Weiss NS, Morgan TR, et al. Practice changing RCT design and rationale: Abbreviated MRI plus AFP vs. ultrasound plus AFP for HCC surveillance in cirrhosis (PREMIUM study). JHEP Reports. 2026;8(2):101666.","journal-title":"JHEP Reports."},{"issue":"6","key":"2718_CR217","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s11912-025-01681-3","volume":"27","author":"W Yang","year":"2025","unstructured":"Yang W, Nguyen R, Safri F, Shiddiky MJA, Warkiani ME, George J, et al. Liquid Biopsy in hepatocellular carcinoma: ctDNA as a potential biomarker for diagnosis and prognosis. Curr Oncol Rep. 2025;27(6):791\u2013802.","journal-title":"Curr Oncol Rep"},{"key":"2718_CR218","doi-asserted-by":"crossref","unstructured":"Kapelanski-Lamoureux A, Lazaris A, Meti N, Metrakos P. Current immunotherapy strategies and emerging biomarkers for the treatment of hepatocellular carcinoma. Cancers (Basel).\u00a02025;17(23):3870.","DOI":"10.3390\/cancers17233870"},{"issue":"2","key":"2718_CR219","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ccell.2024.01.007","volume":"42","author":"X Yang","year":"2024","unstructured":"Yang X, Yang C, Zhang S, Geng H, Zhu AX, Bernards R, et al. Precision treatment in advanced hepatocellular carcinoma. Cancer Cell. 2024;42(2):180\u201397.","journal-title":"Cancer Cell"},{"issue":"1","key":"2718_CR220","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1021\/acs.jproteome.4c00752","volume":"24","author":"A Athanasiou","year":"2025","unstructured":"Athanasiou A, Kureshi N, Wittig A, Sterner M, Huber R, Palma NA, et al. Biomarker discovery for early detection of pancreatic ductal adenocarcinoma (PDAC) using multiplex proteomics technology. J Proteome Res. 2025;24(1):315\u201322.","journal-title":"J Proteome Res"},{"issue":"2","key":"2718_CR221","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.24.31151","volume":"223","author":"C Huang","year":"2024","unstructured":"Huang C, Hecht EM, Soloff EV, Tiwari HA, Bhosale PR, Dasayam A, et al. Imaging for early detection of pancreatic ductal adenocarcinoma: updates and challenges in the implementation of screening and surveillance programs. AJR Am J Roentgenol. 2024;223(2):e2431151.","journal-title":"AJR Am J Roentgenol"},{"key":"2718_CR222","doi-asserted-by":"crossref","unstructured":"Theocharopoulos C, Machairas N, Ziogas IA, Mungo B, Del Chiaro M, Glatzounis GK, et al. Personalizing treatment for pancreatic ductal adenocarcinoma: the emerging role of minimal residual disease in perioperative decision-making. Cancers (Basel). 2025;18(1):94.","DOI":"10.3390\/cancers18010094"},{"issue":"10","key":"2718_CR223","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1093\/oncolo\/oyae155","volume":"29","author":"GP Botta","year":"2024","unstructured":"Botta GP, Abdelrahim M, Drengler RL, Aushev VN, Esmail A, Laliotis G, et al. Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma. Oncologist. 2024;29(10):859\u201369.","journal-title":"Oncologist"},{"key":"2718_CR224","doi-asserted-by":"crossref","unstructured":"Domaga\u0142a-Haduch M, D\u0142ugaszek A, Gorzelak-Magiera A, Gisterek-Grocholska I. Current systemic treatment options for advanced pancreatic cancer-an overview article. Biomedicines.\u00a02026;14(1):188.","DOI":"10.3390\/biomedicines14010188"},{"key":"2718_CR225","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217699","volume":"622","author":"K Br\u00e4utigam","year":"2025","unstructured":"Br\u00e4utigam K, Skok K, Szymonski K, Rift CV, Karamitopoulou E. Tumor immune microenvironment in pancreatic ductal adenocarcinoma revisited - exploring the \u201cspace.\u201d Cancer Lett. 2025;622:217699.","journal-title":"Cancer Lett"},{"issue":"12","key":"2718_CR226","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1093\/jnci\/djaf209","volume":"117","author":"DW Ebner","year":"2025","unstructured":"Ebner DW, Fendrick AM, Kisiel JB, Estes C, Vahdat V, Ozbay AB, et al. Evaluating benefit-to-burden ratios of the established and emerging colorectal cancer screening strategies. J Natl Cancer Inst. 2025;117(12):2653\u201360.","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"2718_CR227","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1038\/s41591-024-03254-6","volume":"30","author":"Y Nakamura","year":"2024","unstructured":"Nakamura Y, Watanabe J, Akazawa N, Hirata K, Kataoka K, Yokota M, et al. ctDNA-based molecular residual disease and survival in resectable colorectal cancer. Nat Med. 2024;30(11):3272\u201383.","journal-title":"Nat Med"},{"key":"2718_CR228","doi-asserted-by":"publisher","first-page":"104775","DOI":"10.1016\/j.critrevonc.2025.104775","volume":"212","author":"E Chen","year":"2025","unstructured":"Chen E, Zhou W. Immunotherapy in microsatellite-stable colorectal cancer: strategies to overcome resistance. Crit Rev Oncol Hematol. 2025;212:104775.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10493","key":"2718_CR229","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1016\/S0140-6736(25)00803-7","volume":"405","author":"N Houssami","year":"2025","unstructured":"Houssami N. Breast cancer screening at a crossroads: supplemental imaging for dense breasts. Lancet. 2025;405(10493):1887\u20139.","journal-title":"Lancet"},{"issue":"5s","key":"2718_CR230","doi-asserted-by":"publisher","first-page":"S405","DOI":"10.1016\/j.jacr.2025.02.023","volume":"22","author":"LV Paulis","year":"2025","unstructured":"Paulis LV, Lewin AA, Weinstein SP, Baron P, Dayaratna S, Dodelzon K, et al. ACR appropriateness Criteria\u00ae Supplemental breast cancer screening based on breast density: 2024 Update. J Am Coll Radiol. 2025;22(5s):S405\u201323.","journal-title":"J Am Coll Radiol"},{"key":"2718_CR231","doi-asserted-by":"publisher","first-page":"1634859","DOI":"10.3389\/fonc.2025.1634859","volume":"15","author":"S Easaw","year":"2025","unstructured":"Easaw S, Hsu J, Steuerwald N, Heeke AL. Liquid clues: tracking early-stage breast cancer with ctDNA - a mini review. Front Oncol. 2025;15:1634859.","journal-title":"Front Oncol"},{"issue":"1","key":"2718_CR232","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41523-025-00873-1","volume":"12","author":"A Sanjari Moghaddam","year":"2025","unstructured":"Sanjari Moghaddam A, Lu KY, Nasrollahi E, Oji L, Homeniuk A, Amosu O, et al. Biomarker prediction of immunotherapy response in breast cancer: from single markers to multi-omics integration. NPJ Breast Cancer. 2025;12(1):10.","journal-title":"NPJ Breast Cancer"},{"key":"2718_CR233","doi-asserted-by":"crossref","unstructured":"Khan A, Sisodiya S, Aftab M, Tanwar P, Hussain S, Gupta V. Mechanisms and therapeutic strategies for endocrine resistance in breast cancer: a comprehensive review and meta-analysis. Cancers (Basel). 2025;17(10):1653.","DOI":"10.3390\/cancers17101653"},{"key":"2718_CR234","doi-asserted-by":"crossref","unstructured":"Cai WL, Chen JF, Chen H, Wingrove E, Kurley SJ, Chan LH, et al. Human WDR5 promotes breast cancer growth and metastasis via KMT2-independent translation regulation. Elife. 2022;11:e78163.","DOI":"10.7554\/eLife.78163"},{"issue":"5","key":"2718_CR235","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1111\/cas.15300","volume":"113","author":"BQ Shan","year":"2022","unstructured":"Shan BQ, Wang XM, Zheng L, Han Y, Gao J, Lv MD, et al. DCAF13 promotes breast cancer cell proliferation by ubiquitin inhibiting PERP expression. Cancer Sci. 2022;113(5):1587\u2013600.","journal-title":"Cancer Sci"},{"issue":"1","key":"2718_CR236","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12935-025-03678-1","volume":"25","author":"Y Jia","year":"2025","unstructured":"Jia Y, Zhang L, Zhou W, Chen S, Zhang H, Liu L, et al. Rack1 promotes breast cancer stemness properties and tumorigenesis through the E2F1-SOX2 axis. Cancer Cell Int. 2025;25(1):40.","journal-title":"Cancer Cell Int"},{"key":"2718_CR237","doi-asserted-by":"publisher","first-page":"120682","DOI":"10.1016\/j.lfs.2022.120682","volume":"303","author":"A Sharma","year":"2022","unstructured":"Sharma A, Thacker G, Mishra M, Singh AK, Upadhyay V, Sanyal S, et al. SOX4-mediated FBW7 transcriptional upregulation confers Tamoxifen resistance in ER+ breast cancers via GATA3 downregulation. Life Sci. 2022;303:120682.","journal-title":"Life Sci"},{"issue":"1","key":"2718_CR238","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s13046-023-02767-1","volume":"42","author":"S Chen","year":"2023","unstructured":"Chen S, Leng P, Guo J, Zhou H. FBXW7 in breast cancer: mechanism of action and therapeutic potential. J Exp Clin Cancer Res. 2023;42(1):226.","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"2718_CR239","first-page":"563","volume":"13","author":"Q Guo","year":"2020","unstructured":"Guo Q, Cheng K, Wang X, Li X, Yu Y, Hua Y, et al. Expression of HDAC1 and RBBP4 correlate with clinicopathologic characteristics and prognosis in breast cancer. Int J Clin Exp Pathol. 2020;13(3):563\u201372.","journal-title":"Int J Clin Exp Pathol"},{"issue":"1","key":"2718_CR240","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s12967-025-06270-3","volume":"23","author":"Y Xi","year":"2025","unstructured":"Xi Y, Wang R, Qu M, Pan Q, Wang M, Ai X, et al. Super-enhancer-hijacking RBBP7 potentiates metastasis and stemness of breast cancer via recruiting NuRD complex subunit LSD1. J Transl Med. 2025;23(1):266.","journal-title":"J Transl Med"},{"key":"2718_CR241","doi-asserted-by":"publisher","first-page":"102072","DOI":"10.1016\/j.tice.2023.102072","volume":"82","author":"Y Shan","year":"2023","unstructured":"Shan Y, Mao B, Jin Y, You Y, Wang Y, Shen K, et al. Expression of DDB1 is associated with subtypes of epithelial ovarian cancer and predicts clinical outcomes. Tissue Cell. 2023;82:102072.","journal-title":"Tissue Cell"},{"issue":"1","key":"2718_CR242","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/s41392-022-01253-y","volume":"7","author":"Y Meng","year":"2022","unstructured":"Meng Y, Qiu L, Zeng X, Hu X, Zhang Y, Wan X, et al. Targeting CRL4 suppresses chemoresistant ovarian cancer growth by inducing mitophagy. Signal Transduct Target Ther. 2022;7(1):388.","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"2718_CR243","doi-asserted-by":"publisher","first-page":"119077","DOI":"10.1016\/j.bbamcr.2021.119077","volume":"1868","author":"FY Zhao","year":"2021","unstructured":"Zhao FY, Zhang Q, Wang JM, Jiang JY, Huyan LY, Liu BQ, et al. BAG3 epigenetically regulates GALNT10 expression via WDR5 and facilitates the stem cell-like properties of platin-resistant ovarian cancer cells. Biochim Biophys Acta Mol Cell Res. 2021;1868(9):119077.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"issue":"11","key":"2718_CR244","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1038\/s41418-023-01226-w","volume":"30","author":"Y Pi","year":"2023","unstructured":"Pi Y, Feng Q, Sun F, Wang Z, Zhao Y, Chen D, et al. Loss of SMURF2 expression enhances RACK1 stability and promotes ovarian cancer progression. Cell Death Differ. 2023;30(11):2382\u201392.","journal-title":"Cell Death Differ"},{"issue":"10","key":"2718_CR245","doi-asserted-by":"publisher","first-page":"e1892-e","DOI":"10.1038\/cddis.2015.250","volume":"6","author":"E Hedstr\u00f6m","year":"2015","unstructured":"Hedstr\u00f6m E, Pederiva C, Farnebo J, Nodin B, Jirstr\u00f6m K, Brennan DJ, et al. Downregulation of the cancer susceptibility protein WRAP53\u03b2 in epithelial ovarian cancer leads to defective DNA repair and poor clinical outcome. Cell Death Dis. 2015;6(10):e1892-e.","journal-title":"Cell Death Dis"},{"key":"2718_CR246","doi-asserted-by":"crossref","unstructured":"Di Fiore R, Suleiman S, Drago-Ferrante R, Subbannayya Y, Suleiman S, Vasileva-Slaveva M, et al. The role of FBXW7 in gynecologic malignancies. Cells.\u00a02023;12(10):1415.","DOI":"10.3390\/cells12101415"},{"key":"2718_CR247","doi-asserted-by":"publisher","first-page":"123712","DOI":"10.1016\/j.lfs.2025.123712","volume":"376","author":"X Ma","year":"2025","unstructured":"Ma X, Xu Z, Wang X, Sun S, Zhang J, Tang R, et al. Aberrant WDR5 promotes the progression of cervical cancer through the YAP1- CTGF pathway. Life Sci. 2025;376:123712.","journal-title":"Life Sci"},{"issue":"7","key":"2718_CR248","doi-asserted-by":"publisher","first-page":"3342","DOI":"10.1080\/01443615.2022.2125294","volume":"42","author":"Z Song","year":"2022","unstructured":"Song Z, Li H. Circ_0072995 drives cervical cancer development by regulating the miR-29a\/WDR5 axis. J Obstet Gynaecol. 2022;42(7):3342\u20138.","journal-title":"J Obstet Gynaecol"},{"key":"2718_CR249","doi-asserted-by":"crossref","unstructured":"Xu L, Li J, Tursun M, Hai Y, Tursun H, Mamtimin B, et al. Receptor for activated C kinase 1 promotes cervical cancer lymph node metastasis via the glycolysis\u2011dependent AKT\/mTOR signaling. Int J Oncol.\u00a02022;61(1):83.","DOI":"10.3892\/ijo.2022.5373"},{"issue":"11","key":"2718_CR250","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/s41388-023-02595-9","volume":"42","author":"C Zhang","year":"2023","unstructured":"Zhang C, Jiang H, Yuan L, Liao Y, Liu P, Du Q, et al. CircVPRBP inhibits nodal metastasis of cervical cancer by impeding RACK1 O-GlcNAcylation and stability. Oncogene. 2023;42(11):793\u2013807.","journal-title":"Oncogene"},{"key":"2718_CR251","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.omtn.2018.10.007","volume":"13","author":"LM Liao","year":"2018","unstructured":"Liao LM, Zhang FH, Yao GJ, Ai SF, Zheng M, Huang L. Role of long noncoding RNA 799 in the metastasis of cervical cancer through upregulation of TBL1XR1 expression. Mol Ther Nucleic Acids. 2018;13:580\u20139.","journal-title":"Mol Ther Nucleic Acids"},{"key":"2718_CR252","doi-asserted-by":"publisher","first-page":"101211","DOI":"10.1016\/j.neo.2025.101211","volume":"67","author":"Q Zhou","year":"2025","unstructured":"Zhou Q, Yu H, Dong A, Yi J, Li J, Li X, et al. The TRIM22-CDT2 axis is the key mediator of the p53-Rb signals in growth control of HPV-positive cervical carcinoma cells. Neoplasia. 2025;67:101211.","journal-title":"Neoplasia"},{"issue":"1","key":"2718_CR253","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s12672-023-00775-3","volume":"14","author":"G Singh","year":"2023","unstructured":"Singh G, Sharma SK, Dorata A, Singh SK. MiR-17 ~ 92 suppresses proliferation and invasion of cervical cancer cells by inhibiting cell cycle regulator Cdt2. Discov Oncol. 2023;14(1):172.","journal-title":"Discov Oncol"},{"issue":"6","key":"2718_CR254","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1089\/gtmb.2018.0278","volume":"23","author":"F Liu","year":"2019","unstructured":"Liu F, Zou Y, Wang F, Yang B, Zhang Z, Luo Y, et al. FBXW7 mutations promote cell proliferation, migration, and invasion in cervical cancer. Genet Test Mol Biomarkers. 2019;23(6):409\u201317.","journal-title":"Genet Test Mol Biomarkers"},{"key":"2718_CR255","doi-asserted-by":"publisher","first-page":"1637372","DOI":"10.3389\/or.2025.1637372","volume":"19","author":"X Zhang","year":"2025","unstructured":"Zhang X, Chen Y, Li M, Zhou X, Song Q. METTL1 in human cancers: recognition of their functions, mechanisms and therapeutic value. Oncol Rev. 2025;19:1637372.","journal-title":"Oncol Rev"},{"issue":"1","key":"2718_CR256","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-32320-3","volume":"16","author":"Y Lee","year":"2025","unstructured":"Lee Y, Park SY, Shim BS, Kim B, Kim SH. miR-193a-5p-mediated inhibition of the METTL1\/COX-2 axis is critical for Astragalin-induced apoptosis in cervical cancer. Sci Rep. 2025;16(1):2463.","journal-title":"Sci Rep"},{"key":"2718_CR257","doi-asserted-by":"crossref","unstructured":"Wang W, Liu H, Ma X, Ma J. BOP1: a pivotal prognostic biomarker in clear cell renal cell carcinoma uncovered through integrated bulk and single-cell sequencing. Asian J Surg. 2025;48(4):2375\u20137.","DOI":"10.1016\/j.asjsur.2024.10.159"},{"issue":"10","key":"2718_CR258","doi-asserted-by":"publisher","first-page":"e13676","DOI":"10.1111\/cpr.13676","volume":"57","author":"H Wei","year":"2024","unstructured":"Wei H, Wang Z, Huang Y, Gao L, Wang W, Liu S, et al. DCAF2 regulates the proliferation and differentiation of mouse progenitor spermatogonia by targeting p21 and thymine DNA glycosylase. Cell Prolif. 2024;57(10):e13676.","journal-title":"Cell Prolif"},{"issue":"1","key":"2718_CR259","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1186\/s12885-025-14749-x","volume":"25","author":"Z Wang","year":"2025","unstructured":"Wang Z, Li H, Hou X, Zhang S, Deng K, Wang N, et al. Multi-omics analysis of bidirectional liquid-liquid phase separation signatures reveals immunotherapy response and prognosis in renal cell carcinoma. BMC Cancer. 2025;25(1):1314.","journal-title":"BMC Cancer"},{"issue":"7","key":"2718_CR260","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.7150\/thno.106018","volume":"15","author":"S Chen","year":"2025","unstructured":"Chen S, Xiong K, Liu J, Yao S, Li M, Yu J, et al. FBXW7\/GSK3\u03b2-mediated proline-rich 11 degradation promotes oxidative DNA damage and inhibits tumor progression in renal cell carcinoma. Theranostics. 2025;15(7):2814\u201333.","journal-title":"Theranostics"},{"issue":"1","key":"2718_CR261","doi-asserted-by":"publisher","first-page":"20251140","DOI":"10.1515\/biol-2025-1140","volume":"20","author":"Y Wu","year":"2025","unstructured":"Wu Y, Li XY, Chen JD, Pan YF. BAP1 complexes with YY1 and RBBP7 and its downstream targets in ccRCC cells. Open Life Sci. 2025;20(1):20251140.","journal-title":"Open Life Sci"},{"key":"2718_CR262","doi-asserted-by":"publisher","first-page":"102202","DOI":"10.1016\/j.tranon.2024.102202","volume":"51","author":"Y Liu","year":"2025","unstructured":"Liu Y, Zhan Y, Liu J, Shen Z, Hu Y, Zhong L, et al. The 7-Methylguanosine (m7G) methylation METTL1 acts as a potential biomarker of clear cell renal cell carcinoma progression. Transl Oncol. 2025;51:102202.","journal-title":"Transl Oncol"},{"issue":"1","key":"2718_CR263","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s13046-021-01989-5","volume":"40","author":"J Zhang","year":"2021","unstructured":"Zhang J, Zhou Q, Xie K, Cheng L, Peng S, Xie R, et al. Targeting WD repeat domain 5 enhances chemosensitivity and inhibits proliferation and programmed death-ligand 1 expression in bladder cancer. J Exp Clin Cancer Res. 2021;40(1):203.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"2718_CR264","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41389-023-00493-z","volume":"12","author":"G Wang","year":"2023","unstructured":"Wang G, He X, Dai H, Lin L, Cao W, Fu Y, et al. WDR4 promotes the progression and lymphatic metastasis of bladder cancer via transcriptional down-regulation of ARRB2. Oncogenesis. 2023;12(1):47.","journal-title":"Oncogenesis"},{"key":"2718_CR265","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/3369858","volume":"2022","author":"Y Luo","year":"2022","unstructured":"Luo Y, He Z, Liu W, Zhou F, Liu T, Wang G. DTL is a prognostic biomarker and promotes bladder cancer progression through regulating the AKT\/mTOR axis. Oxid Med Cell Longev. 2022;2022:3369858.","journal-title":"Oxid Med Cell Longev"},{"issue":"1","key":"2718_CR266","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s10616-023-00599-7","volume":"76","author":"J Yu","year":"2024","unstructured":"Yu J, Ge S. PRPF19 functions in DNA damage repair and gemcitabine sensitivity via regulating DDB1 in bladder cancer cells. Cytotechnology. 2024;76(1):85\u201396.","journal-title":"Cytotechnology"},{"issue":"2","key":"2718_CR267","doi-asserted-by":"publisher","first-page":"112807","DOI":"10.1016\/j.yexcr.2021.112807","volume":"407","author":"F Qiu","year":"2021","unstructured":"Qiu F, Jin Y, Pu J, Huang Y, Hou J, Zhao X, et al. Aberrant FBXW7-mediated ubiquitination and degradation of ZMYND8 enhances tumor progression and stemness in bladder cancer. Exp Cell Res. 2021;407(2):112807.","journal-title":"Exp Cell Res"},{"issue":"10290","key":"2718_CR268","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1016\/S0140-6736(21)00731-5","volume":"397","author":"U Menon","year":"2021","unstructured":"Menon U, Gentry-Maharaj A, Burnell M, Singh N, Ryan A, Karpinskyj C, et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2021;397(10290):2182\u201393.","journal-title":"Lancet"},{"key":"2718_CR269","doi-asserted-by":"crossref","unstructured":"Rios-Doria E, Reichel JB, Radke MR, Manhardt E, Rubin-Saika M, Lockwood C, et al. Dynamic monitoring of recurrent ovarian cancer using serial ctDNA: a real-world case series. Curr Oncol.\u00a02025;32(10):585.","DOI":"10.3390\/curroncol32100585"},{"key":"2718_CR270","doi-asserted-by":"crossref","unstructured":"Apelian S, Martincuks A, Whittum M, Yasukawa M, Nguy L, Mathyk B, et al. PARP inhibitors in ovarian cancer: resistance mechanisms, clinical evidence, and evolving strategies. Biomedicines.\u00a02025;13(5):1126.","DOI":"10.3390\/biomedicines13051126"},{"issue":"1","key":"2718_CR271","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jasc.2024.09.003","volume":"14","author":"MJ Thrall","year":"2025","unstructured":"Thrall MJ, McCarthy E, Mito JK, Rao J. Triage options for positive high-risk HPV results from HPV-based cervical cancer screening: a review of the potential alternatives to Papanicolaou test cytology. J Am Soc Cytopathol. 2025;14(1):11\u201322.","journal-title":"J Am Soc Cytopathol"},{"key":"2718_CR272","doi-asserted-by":"crossref","unstructured":"Ouh YT, Kim HY, Yi KW, Lee NW, Kim HJ, Min KJ. Enhancing cervical cancer screening: review of p16\/Ki-67 dual staining as a promising triage strategy. Diagnostics (Basel). 2024;14(4):451.","DOI":"10.3390\/diagnostics14040451"},{"issue":"10434","key":"2718_CR273","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(24)00317-9","volume":"403","author":"D Lorusso","year":"2024","unstructured":"Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, Ramos-Elias P, et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial. Lancet. 2024;403(10434):1341\u201350.","journal-title":"Lancet"},{"issue":"4","key":"2718_CR274","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1200\/JCO.23.00954","volume":"42","author":"K Han","year":"2024","unstructured":"Han K, Zou J, Zhao Z, Baskurt Z, Zheng Y, Barnes E, et al. Clinical validation of human papilloma virus circulating tumor DNA for early detection of residual disease after chemoradiation in cervical cancer. J Clin Oncol. 2024;42(4):431\u201340.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2718_CR275","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41588-024-01662-5","volume":"56","author":"J Hu","year":"2024","unstructured":"Hu J, Wang SG, Hou Y, Chen Z, Liu L, Li R, et al. Multi-omic profiling of clear cell renal cell carcinoma identifies metabolic reprogramming associated with disease progression. Nat Genet. 2024;56(3):442\u201357.","journal-title":"Nat Genet"},{"key":"2718_CR276","doi-asserted-by":"crossref","unstructured":"Hwang J, Holl E, Wu Y, Agarwal A, Starr MD, Reyes Martinez MA, et al. Circulating immune biomarkers correlating with response in patients with metastatic renal cell carcinoma on immunotherapy. JCI Insight.\u00a02025;10(4):e185963.","DOI":"10.1172\/jci.insight.185963"},{"key":"2718_CR277","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.euros.2021.12.006","volume":"37","author":"L Geertsen","year":"2022","unstructured":"Geertsen L, Koldby KM, Thomassen M, Kruse T, Lund L. Circulating tumor DNA in patients with renal cell carcinoma. A systematic review of the literature. Eur Urol Open Sci. 2022;37:27\u201335.","journal-title":"Eur Urol Open Sci."},{"issue":"8","key":"2718_CR278","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1056\/NEJMoa2313906","volume":"391","author":"TK Choueiri","year":"2024","unstructured":"Choueiri TK, Powles T, Peltola K, de Velasco G, Burotto M, Suarez C, et al. Belzutifan versus Everolimus for advanced renal-cell carcinoma. N Engl J Med. 2024;391(8):710\u201321.","journal-title":"N Engl J Med"},{"issue":"11","key":"2718_CR279","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1002\/1878-0261.13639","volume":"18","author":"HM Vedeld","year":"2024","unstructured":"Vedeld HM, Pharo H, S\u00f8rb\u00f8 AK, Brandt-Winge S, Five MB, Jeanmougin M, et al. Distinct longitudinal patterns of urine tumor DNA in patients undergoing surveillance for bladder cancer. Mol Oncol. 2024;18(11):2684\u201395.","journal-title":"Mol Oncol"},{"issue":"10","key":"2718_CR280","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, et al. Enfortumab Vedotin and Pembrolizumab in untreated advanced urothelial cancer. N Engl J Med. 2024;390(10):875\u201388.","journal-title":"N Engl J Med"},{"issue":"1","key":"2718_CR281","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1148\/rg.2019180069","volume":"39","author":"GS Shroff","year":"2019","unstructured":"Shroff GS, Truong MT, Carter BW, Benveniste MF, Kanagal-Shamanna R, Rauch G, et al. Leukemic involvement in the Thorax. Radiographics. 2019;39(1):44\u201361.","journal-title":"Radiographics"},{"key":"2718_CR282","doi-asserted-by":"publisher","first-page":"103348","DOI":"10.1016\/j.eclinm.2025.103348","volume":"86","author":"NS Chandhok","year":"2025","unstructured":"Chandhok NS, Sekeres MA. Measurable residual disease in hematologic malignancies: a biomarker in search of a standard. EClinicalMedicine. 2025;86:103348.","journal-title":"EClinicalMedicine"},{"key":"2718_CR283","doi-asserted-by":"crossref","unstructured":"Chatzilygeroudi T, Karantanos T, Pappa V. Unraveling Venetoclax resistance: navigating the future of HMA\/Venetoclax-refractory AML in the molecular era. Cancers (Basel).\u00a02025;17(9):1586.","DOI":"10.3390\/cancers17091586"},{"issue":"1","key":"2718_CR284","doi-asserted-by":"publisher","first-page":"5397","DOI":"10.1038\/s41467-021-25664-7","volume":"12","author":"A Khateb","year":"2021","unstructured":"Khateb A, Deshpande A, Feng Y, Finlay D, Lee JS, Lazar I, et al. The ubiquitin ligase RNF5 determines acute myeloid leukemia growth and susceptibility to histone deacetylase inhibitors. Nat Commun. 2021;12(1):5397.","journal-title":"Nat Commun"},{"issue":"22","key":"2718_CR285","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1101\/gad.306753.117","volume":"31","author":"TM Franks","year":"2017","unstructured":"Franks TM, McCloskey A, Shokirev MN, Benner C, Rathore A, Hetzer MW. Nup98 recruits the Wdr82-Set1A\/COMPASS complex to promoters to regulate H3K4 trimethylation in hematopoietic progenitor cells. Genes Dev. 2017;31(22):2222\u201334.","journal-title":"Genes Dev"},{"issue":"11","key":"2718_CR286","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1038\/s44319-025-00448-y","volume":"26","author":"C Moison","year":"2025","unstructured":"Moison C, Mendoza-Sanchez R, Gracias D, Schuetz DA, Spinella JF, Girard S, et al. DDB1 engagement defines the selectivity of S656 analogs for cyclin K degradation over CDK inhibition. EMBO Rep. 2025;26(11):2836\u201354.","journal-title":"EMBO Rep"},{"issue":"1","key":"2718_CR287","doi-asserted-by":"publisher","first-page":"5604","DOI":"10.1038\/s41467-024-49882-x","volume":"15","author":"GP Grothusen","year":"2024","unstructured":"Grothusen GP, Chang R, Cao Z, Zhou N, Mittal M, Datta A, et al. DCAF15 control of cohesin dynamics sustains acute myeloid leukemia. Nat Commun. 2024;15(1):5604.","journal-title":"Nat Commun"},{"issue":"10","key":"2718_CR288","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.3324\/haematol.2009.012047","volume":"94","author":"CG Mullighan","year":"2009","unstructured":"Mullighan CG. Mutations of NOTCH1, FBXW7, and prognosis in T-lineage acute lymphoblastic leukemia. Haematologica. 2009;94(10):1338\u201340.","journal-title":"Haematologica"},{"issue":"1\u20132","key":"2718_CR289","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s11010-013-1798-0","volume":"384","author":"D Zhang","year":"2013","unstructured":"Zhang D, Wang Q, Zhu T, Cao J, Zhang X, Wang J, et al. RACK1 promotes the proliferation of THP1 acute myeloid leukemia cells. Mol Cell Biochem. 2013;384(1\u20132):197\u2013202.","journal-title":"Mol Cell Biochem"},{"issue":"35","key":"2718_CR290","doi-asserted-by":"publisher","first-page":"e2408889121","DOI":"10.1073\/pnas.2408889121","volume":"121","author":"CT Meyer","year":"2024","unstructured":"Meyer CT, Smith BN, Wang J, Teuscher KB, Grieb BC, Howard GC, et al. Expanded profiling of WD repeat domain 5 inhibitors reveals actionable strategies for the treatment of hematologic malignancies. Proc Natl Acad Sci U S A. 2024;121(35):e2408889121.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2718_CR291","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.1182\/blood-2023-186680","volume":"142","author":"C Ji","year":"2023","unstructured":"Ji C, Liu X. Aberrant translation regulated by METTL1\/WDR4-mediated tRNA N 7-methylguanosine modification drives DLBCL progression. Blood. 2023;142:5727.","journal-title":"Blood"},{"key":"2718_CR292","first-page":"181","volume":"18","author":"WJ Zhang","year":"2024","unstructured":"Zhang WJ, Hu CL, Guo BL, Liang XP, Wang CY, Yang T. STAT5B suppresses ferroptosis by promoting DCAF13 transcription to regulate p53\/xCT pathway to promote mantle cell lymphoma progression. Biologics. 2024;18:181\u201393.","journal-title":"Biologics"},{"issue":"12","key":"2718_CR293","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1158\/0008-5472.CAN-19-2247","volume":"80","author":"R Saffie","year":"2020","unstructured":"Saffie R, Zhou N, Rolland D, \u00d6nder \u00d6, Basrur V, Campbell S, et al. FBXW7 triggers degradation of KMT2D to favor growth of diffuse large B-cell lymphoma cells. Cancer Res. 2020;80(12):2498\u2013511.","journal-title":"Cancer Res"},{"key":"2718_CR294","doi-asserted-by":"publisher","first-page":"1620895","DOI":"10.3389\/fimmu.2025.1620895","volume":"16","author":"Z Wang","year":"2025","unstructured":"Wang Z, Feng S, Yao X, Zhao R, Li Y, Zheng M, et al. Molecular pathology of lymphoma and its treatment strategies: from mechanistic elucidation to precision medicine. Front Immunol. 2025;16:1620895.","journal-title":"Front Immunol"},{"issue":"10","key":"2718_CR295","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1093\/neuonc\/noad100","volume":"25","author":"F Sahm","year":"2023","unstructured":"Sahm F, Brandner S, Bertero L, Capper D, French PJ, Figarella-Branger D, et al. Molecular diagnostic tools for the World Health Organization (WHO) 2021 classification of gliomas, glioneuronal and neuronal tumors; an EANO guideline. Neuro Oncol. 2023;25(10):1731\u201349.","journal-title":"Neuro Oncol"},{"key":"2718_CR296","doi-asserted-by":"publisher","first-page":"1714287","DOI":"10.3389\/fonc.2025.1714287","volume":"15","author":"R P\u00e9rez-Alfayate","year":"2025","unstructured":"P\u00e9rez-Alfayate R, Paz-Cabezas M, P\u00e9rez-Segura P, Sanchez Del Hoyo R, Cabezas-Camarero S. Cerebrospinal fluid ctDNA as a diagnostic and prognostic tool in gliomas: a systematic review and meta-analysis. Front Oncol. 2025;15:1714287.","journal-title":"Front Oncol"},{"issue":"12","key":"2718_CR297","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1038\/s41423-024-01226-x","volume":"21","author":"Y Liu","year":"2024","unstructured":"Liu Y, Zhou F, Ali H, Lathia JD, Chen P. Immunotherapy for glioblastoma: current state, challenges, and future perspectives. Cell Mol Immunol. 2024;21(12):1354\u201375.","journal-title":"Cell Mol Immunol"},{"key":"2718_CR298","doi-asserted-by":"publisher","first-page":"216078","DOI":"10.1016\/j.canlet.2023.216078","volume":"557","author":"J Li","year":"2023","unstructured":"Li J, Song C, Gu J, Li C, Zang W, Shi L, et al. RBBP4 regulates the expression of the Mre11-Rad50-NBS1 (MRN) complex and promotes DNA double-strand break repair to mediate glioblastoma chemoradiotherapy resistance. Cancer Lett. 2023;557:216078.","journal-title":"Cancer Lett"},{"key":"2718_CR299","doi-asserted-by":"publisher","first-page":"638802","DOI":"10.3389\/fonc.2021.638802","volume":"11","author":"X Ye","year":"2021","unstructured":"Ye X, Liu X, Gao M, Gong L, Tian F, Shen Y, et al. CUL4B Promotes temozolomide resistance in gliomas by epigenetically repressing CDNK1A transcription. Front Oncol. 2021;11:638802.","journal-title":"Front Oncol"},{"issue":"3","key":"2718_CR300","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1158\/0008-5472.CAN-21-0384","volume":"82","author":"Z Yang","year":"2022","unstructured":"Yang Z, Hu N, Wang W, Hu W, Zhou S, Shi J, et al. Loss of FBXW7 correlates with Increased IDH1 expression in glioma and enhances IDH1-mutant cancer cell sensitivity to radiation. Cancer Res. 2022;82(3):497\u2013509.","journal-title":"Cancer Res"},{"issue":"1","key":"2718_CR301","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41392-023-01666-3","volume":"8","author":"J Qu","year":"2023","unstructured":"Qu J, Qiu B, Zhang Y, Hu Y, Wang Z, Guan Z, et al. The tumor-enriched small molecule gambogic amide suppresses glioma by targeting WDR1-dependent cytoskeleton remodeling. Signal Transduct Target Ther. 2023;8(1):424.","journal-title":"Signal Transduct Target Ther"},{"key":"2718_CR302","doi-asserted-by":"crossref","unstructured":"Dowell N, Begum S, Muzaffar J, Boelaert K, Nieto H. Comparing the diagnostic accuracy of Afirma GSC to ThyroSeq V3 in cytologically indeterminate thyroid nodules. Eur Thyroid J.\u00a02025;14(6):e250296.","DOI":"10.1530\/ETJ-25-0296"},{"issue":"2","key":"2718_CR303","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s00259-024-06991-5","volume":"52","author":"P Petranovi\u0107 Ov\u010dari\u010dek","year":"2025","unstructured":"Petranovi\u0107 Ov\u010dari\u010dek P, de Keizer B, Campenn\u00ec A, Kreissl MC, Deandreis D, Tuncel M, et al. Radioiodine-refractory thyroid cancer\u2014is it time to change the definition in light of novel redifferentiation therapies? Eur J Nucl Med Mol Imaging. 2025;52(2):380\u20135.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2718_CR304","doi-asserted-by":"publisher","first-page":"3762","DOI":"10.12659\/MSM.915847","volume":"25","author":"W Xu","year":"2019","unstructured":"Xu W, Wang L, An Y, Ye J. Expression of WD repeat domain 5 (WDR5) is associated with progression and reduced prognosis in papillary thyroid carcinoma. Med Sci Monit. 2019;25:3762\u201370.","journal-title":"Med Sci Monit"},{"issue":"2","key":"2718_CR305","doi-asserted-by":"publisher","first-page":"e23875","DOI":"10.1016\/j.heliyon.2023.e23875","volume":"10","author":"T Zhou","year":"2024","unstructured":"Zhou T, Ma N, Zhang YL, Chen XH, Luo X, Zhang M, et al. Transcription factor FOXP4 inversely governs tumor suppressor genes and contributes to thyroid cancer progression. Heliyon. 2024;10(2):e23875.","journal-title":"Heliyon"},{"issue":"1","key":"2718_CR306","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13008-024-00139-5","volume":"20","author":"W Luo","year":"2025","unstructured":"Luo W, Xiao Q, Fu Y. ZNF169 promotes thyroid cancer progression via upregulating FBXW10. Cell Div. 2025;20(1):3.","journal-title":"Cell Div"},{"issue":"1","key":"2718_CR307","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/s41419-025-07716-8","volume":"16","author":"W Li","year":"2025","unstructured":"Li W, Xie R, Chen H, Lin J, Zhong M, Zhang J, et al. METTL1-mediated m(7)G tRNA modification drives papillary thyroid cancer progression and metastasis by regulating the codon-specific translation of TNF-\u03b1. Cell Death Dis. 2025;16(1):378.","journal-title":"Cell Death Dis"},{"key":"2718_CR308","doi-asserted-by":"crossref","unstructured":"Zhao Y, Yu T, Sun J, Wang F, Cheng C, He S, et al. Germ-line mutations in WDR77 predispose to familial papillary thyroid cancer. Proc Natl Acad Sci U S A.\u00a02021;118(31):e2026327118.","DOI":"10.1073\/pnas.2026327118"},{"issue":"11","key":"2718_CR309","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1089\/thy.2010.0186","volume":"21","author":"LM Myklebust","year":"2011","unstructured":"Myklebust LM, Akslen LA, Varhaug JE, Lillehaug JR. Receptor for activated protein C kinase 1 (RACK1) is overexpressed in papillary thyroid carcinoma. Thyroid. 2011;21(11):1217\u201325.","journal-title":"Thyroid"},{"issue":"1","key":"2718_CR310","first-page":"e70065","volume":"76","author":"J Burshtein","year":"2026","unstructured":"Burshtein J, Witkowski A, Zakria D, Shah M, Rosenberg A, DeBusk L, et al. Advances in the noninvasive diagnosis of melanoma-40 years beyond the ABCDs. CA Cancer J Clin. 2026;76(1):e70065.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2718_CR311","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41746-025-01980-w","volume":"8","author":"SS Han","year":"2025","unstructured":"Han SS, Cho SI, Fabian G, Navarini AA, Kim MS, Lee DH, et al. Planet-wide performance of a skin disease AI algorithm validated in Korea. NPJ Digit Med. 2025;8(1):603.","journal-title":"NPJ Digit Med"},{"key":"2718_CR312","doi-asserted-by":"publisher","first-page":"1688699","DOI":"10.3389\/fimmu.2025.1688699","volume":"16","author":"X Wang","year":"2025","unstructured":"Wang X, He J, Ding G, Tang Y, Wang Q. Overcoming resistance to PD-1 and CTLA-4 blockade mechanisms and therapeutic strategies. Front Immunol. 2025;16:1688699.","journal-title":"Front Immunol"},{"issue":"6","key":"2718_CR313","doi-asserted-by":"publisher","first-page":"dju107","DOI":"10.1093\/jnci\/dju107","volume":"106","author":"IT Aydin","year":"2014","unstructured":"Aydin IT, Melamed RD, Adams SJ, Castillo-Martin M, Demir A, Bryk D, et al. FBXW7 mutations in melanoma and a new therapeutic paradigm. J Natl Cancer Inst. 2014;106(6):dju107.","journal-title":"J Natl Cancer Inst."},{"key":"2718_CR314","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ebiom.2016.06.023","volume":"10","author":"M Benamar","year":"2016","unstructured":"Benamar M, Guessous F, Du K, Corbett P, Obeid J, Gioeli D, et al. Inactivation of the CRL4-CDT2-SET8\/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma. EBioMedicine. 2016;10:85\u2013100.","journal-title":"EBioMedicine"},{"issue":"4","key":"2718_CR315","doi-asserted-by":"publisher","first-page":"795","DOI":"10.7150\/jca.36905","volume":"11","author":"C Shen","year":"2020","unstructured":"Shen C, Hua H, Gu L, Cao S, Cai H, Yao X, et al. Overexpression of RACK1 predicts poor prognosis in melanoma. J Cancer. 2020;11(4):795\u2013803.","journal-title":"J Cancer"},{"issue":"1","key":"2718_CR316","doi-asserted-by":"publisher","first-page":"5156","DOI":"10.1038\/s41467-020-18973-w","volume":"11","author":"M Napoli","year":"2020","unstructured":"Napoli M, Li X, Ackerman HD, Deshpande AA, Barannikov I, Pisegna MA, et al. Pan-cancer analysis reveals TAp63-regulated oncogenic lncRNAs that promote cancer progression through AKT activation. Nat Commun. 2020;11(1):5156.","journal-title":"Nat Commun"},{"key":"2718_CR317","doi-asserted-by":"crossref","unstructured":"Shin Y, Kim S, Liang G, Ulmer TS, An W. VprBP\/DCAF1 triggers melanomagenic gene silencing through histone H2A phosphorylation. Biomedicines.\u00a02023;11(9):2552.","DOI":"10.3390\/biomedicines11092552"},{"issue":"5","key":"2718_CR318","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1158\/1541-7786.MCR-20-0324","volume":"19","author":"M Pistoni","year":"2021","unstructured":"Pistoni M, Rossi T, Donati B, Torricelli F, Polano M, Ciarrocchi A. Long noncoding RNA NEAT1 acts as a molecular switch for BRD4 transcriptional activity and mediates repression of BRD4\/WDR5 target genes. Mol Cancer Res. 2021;19(5):799\u2013811.","journal-title":"Mol Cancer Res"},{"issue":"1","key":"2718_CR319","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s12672-025-04256-7","volume":"17","author":"Y Xu","year":"2025","unstructured":"Xu Y, Bai Y, Yang F, Yang B, Huang Z, Su L, et al. Decoding osteosarcoma from heterogeneity to precision therapy. Discov Oncol. 2025;17(1):192.","journal-title":"Discov Oncol"},{"issue":"1","key":"2718_CR320","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s12943-024-02105-9","volume":"23","author":"S Yu","year":"2024","unstructured":"Yu S, Yao X. Advances on immunotherapy for osteosarcoma. Mol Cancer. 2024;23(1):192.","journal-title":"Mol Cancer"},{"issue":"9","key":"2718_CR321","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1007\/s10147-025-02813-2","volume":"30","author":"Y Wang","year":"2025","unstructured":"Wang Y, Fujiwara T, Kurozumi T, Ando T, Ishimaru T, Kondo H, et al. Advances in liquid biopsy for bone and soft-tissue sarcomas. Int J Clin Oncol. 2025;30(9):1722\u201333.","journal-title":"Int J Clin Oncol"},{"issue":"18","key":"2718_CR322","doi-asserted-by":"publisher","first-page":"e71040","DOI":"10.1096\/fj.202403381RR","volume":"39","author":"R Yan","year":"2025","unstructured":"Yan R, Gong S, Yang L, Zhang Y, Yan W, Wu H, et al. Single cell geometry regulates self-renewal factors in osteosarcoma cells via WDR5 dependent chromatin methylation. Faseb j. 2025;39(18):e71040.","journal-title":"Faseb j"},{"issue":"23","key":"2718_CR323","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1038\/s41388-023-02695-6","volume":"42","author":"Z Wang","year":"2023","unstructured":"Wang Z, Yu P, Zou Y, Ma J, Han H, Wei W, et al. METTL1\/WDR4-mediated tRNA m(7)G modification and mRNA translation control promote oncogenesis and doxorubicin resistance. Oncogene. 2023;42(23):1900\u201312.","journal-title":"Oncogene"},{"issue":"2","key":"2718_CR324","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/cas.14727","volume":"112","author":"W Yao","year":"2021","unstructured":"Yao W, Yan Q, Du X, Hou J. TNK2-AS1 upregulated by YY1 boosts the course of osteosarcoma through targeting miR-4319\/WDR1. Cancer Sci. 2021;112(2):893\u2013905.","journal-title":"Cancer Sci"},{"issue":"2","key":"2718_CR325","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.3390\/ijms16022294","volume":"16","author":"Z Li","year":"2015","unstructured":"Li Z, Xiao J, Hu K, Wang G, Li M, Zhang J, et al. FBXW7 acts as an independent prognostic marker and inhibits tumor growth in human osteosarcoma. Int J Mol Sci. 2015;16(2):2294\u2013306.","journal-title":"Int J Mol Sci"},{"key":"2718_CR326","doi-asserted-by":"publisher","first-page":"1529657","DOI":"10.3389\/fonc.2025.1529657","volume":"15","author":"G Qiu","year":"2025","unstructured":"Qiu G, Bao Y, Zhang Y, Xu Y, Qiao T, Li C, et al. METTL3-mediated SNHG1 m(6)A modification promotes proliferation and migration through transcriptional regulation of WDR74 in osteosarcoma. Front Oncol. 2025;15:1529657.","journal-title":"Front Oncol"},{"issue":"1","key":"2718_CR327","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s13046-025-03456-x","volume":"44","author":"M Li","year":"2025","unstructured":"Li M, Li N, Fan Y, Zhang Z, Zhou L, Yu Y, et al. WDR3 undergoes phase separation to mediate the therapeutic mechanism of Nilotinib against osteosarcoma. J Exp Clin Cancer Res. 2025;44(1):201.","journal-title":"J Exp Clin Cancer Res"},{"issue":"16","key":"2718_CR328","doi-asserted-by":"publisher","first-page":"11774","DOI":"10.1021\/acs.jmedchem.1c00226","volume":"64","author":"S Tomassi","year":"2021","unstructured":"Tomassi S, Romanelli A, Zwergel C, Valente S, Mai A. Polycomb repressive complex 2 modulation through the development of EZH2-EED interaction inhibitors and EED binders. J Med Chem. 2021;64(16):11774\u201397.","journal-title":"J Med Chem"},{"issue":"4","key":"2718_CR329","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.tcb.2020.01.005","volume":"30","author":"A Panagopoulos","year":"2020","unstructured":"Panagopoulos A, Taraviras S, Nishitani H, Lygerou Z. CRL4(Cdt2): coupling genome stability to ubiquitination. Trends Cell Biol. 2020;30(4):290\u2013302.","journal-title":"Trends Cell Biol"},{"issue":"18","key":"2718_CR330","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1177\/15353702221110645","volume":"247","author":"R An","year":"2022","unstructured":"An R, Wang J, Chen X, Xu R, Hu J, Liu Z, et al. YAP signaling is involved in WDR1-regulated proliferation and migration of non-small-cell lung cancer cells. Exp Biol Med (Maywood). 2022;247(18):1619\u201329.","journal-title":"Exp Biol Med (Maywood)"},{"issue":"1","key":"2718_CR331","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7150\/jca.58982","volume":"13","author":"YZ Li","year":"2022","unstructured":"Li YZ, Zhang C, Pei JP, Zhang WC, Zhang CD, Dai DQ. The functional role of Pescadillo ribosomal biogenesis factor 1 in cancer. J Cancer. 2022;13(1):268\u201377.","journal-title":"J Cancer"},{"issue":"11","key":"2718_CR332","doi-asserted-by":"publisher","first-page":"5498","DOI":"10.3390\/cimb44110372","volume":"44","author":"RB Gadelha","year":"2022","unstructured":"Gadelha RB, Machado CB, Pessoa F, Pantoja LDC, Barreto IV, Ribeiro RM, et al. The role of WRAP53 in cell homeostasis and carcinogenesis onset. Curr Issues Mol Biol. 2022;44(11):5498\u2013515.","journal-title":"Curr Issues Mol Biol"},{"issue":"2","key":"2718_CR333","doi-asserted-by":"publisher","first-page":"166600","DOI":"10.1016\/j.bbadis.2022.166600","volume":"1869","author":"L Liu","year":"2023","unstructured":"Liu L, Guo X, Wang Y, Li G, Yu Y, Song Y, et al. Loss of Wdr5 attenuates MLL-rearranged leukemogenesis by suppressing Myc targets. Biochim Biophys Acta Mol Basis Dis. 2023;1869(2):166600.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"2718_CR334","doi-asserted-by":"publisher","first-page":"115122","DOI":"10.1016\/j.ejca.2024.115122","volume":"216","author":"V Ribrag","year":"2025","unstructured":"Ribrag V, Iglesias L, De Braud F, Ma B, Yokota T, Zander T, et al. A first-in-human phase 1\/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies. Eur J Cancer. 2025;216:115122.","journal-title":"Eur J Cancer"},{"issue":"6","key":"2718_CR335","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/s43018-024-00777-2","volume":"5","author":"NW Mabe","year":"2024","unstructured":"Mabe NW, Perry JA, Malone CF, Stegmaier K. Pharmacological targeting of the cancer epigenome. Nat Cancer. 2024;5(6):844\u201365.","journal-title":"Nat Cancer"},{"key":"2718_CR336","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1097\/01.HS9.0000848744.04551.56","volume":"6","author":"P Bruno","year":"2022","unstructured":"Bruno P, Kanter J, Ziegler J, Stuart B, Ahn J, Dunn J, et al. P1472: interim results of safety, tolerability, pharmacokinetics, and pharmacodynamics from an ongoing open-label study investigating FTX-6058 in adults living with sickle cell disease. HemaSphere. 2022;6:1354\u20135.","journal-title":"HemaSphere"},{"issue":"4","key":"2718_CR337","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/s41401-022-00999-z","volume":"44","author":"QL Han","year":"2023","unstructured":"Han QL, Zhang XL, Ren PX, Mei LH, Lin WH, Wang L, et al. Discovery, evaluation and mechanism study of WDR5-targeted small molecular inhibitors for neuroblastoma. Acta Pharmacol Sin. 2023;44(4):877\u201387.","journal-title":"Acta Pharmacol Sin"},{"key":"2718_CR338","doi-asserted-by":"crossref","unstructured":"Kim JH, Lee EJ, Han KH. An antagonist antibody that inhibits cancer cell growth in vitro through RACK1. Pharmaceuticals (Basel).\u00a02024;17(10):1303.","DOI":"10.3390\/ph17101303"},{"issue":"1","key":"2718_CR339","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1038\/s41598-022-05947-9","volume":"12","author":"AJ Siladi","year":"2022","unstructured":"Siladi AJ, Wang J, Florian AC, Thomas LR, Creighton JH, Matlock BK, et al. WIN site inhibition disrupts a subset of WDR5 function. Sci Rep. 2022;12(1):1848.","journal-title":"Sci Rep"},{"issue":"17","key":"2718_CR340","doi-asserted-by":"publisher","first-page":"eads7876","DOI":"10.1126\/sciadv.ads7876","volume":"11","author":"Y Yu","year":"2025","unstructured":"Yu Y, Yu X, Pan B, Chan HM, Kaniskan H, Jin J, et al. Pharmacologic degradation of WDR5 suppresses oncogenic activities of SS18::SSX and provides a therapeutic of synovial sarcoma. Sci Adv. 2025;11(17):eads7876.","journal-title":"Sci Adv."},{"issue":"19","key":"2718_CR341","doi-asserted-by":"publisher","first-page":"14540","DOI":"10.1021\/acs.jmedchem.1c01059","volume":"64","author":"RK Rej","year":"2021","unstructured":"Rej RK, Wang C, Lu J, Wang M, Petrunak E, Zawacki KP, et al. Discovery of EEDi-5273 as an exceptionally potent and orally efficacious EED inhibitor capable of achieving complete and persistent tumor regression. J Med Chem. 2021;64(19):14540\u201356.","journal-title":"J Med Chem"},{"issue":"6_Supplement","key":"2718_CR342","doi-asserted-by":"publisher","first-page":"6586-","DOI":"10.1158\/1538-7445.AM2024-6586","volume":"84","author":"A Daemen","year":"2024","unstructured":"Daemen A, Yuen N, Wang A, Pankov A, Ulicna L, Chen C, et al. Abstract 6586: ORIC-944, a potent and selective allosteric PRC2 inhibitor with best-in-class properties, demonstrates combination synergy with AR pathway inhibitors in prostate cancer models. Cancer Res. 2024;84(6_Supplement):6586-.","journal-title":"Cancer Res."},{"issue":"3","key":"2718_CR343","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.molcel.2018.03.020","volume":"70","author":"CH Lee","year":"2018","unstructured":"Lee CH, Yu JR, Kumar S, Jin Y, LeRoy G, Bhanu N, et al. Allosteric activation dictates PRC2 activity independent of its recruitment to chromatin. Mol Cell. 2018;70(3):422-34.e6.","journal-title":"Mol Cell"},{"issue":"12","key":"2718_CR344","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1038\/nm.3968","volume":"21","author":"KH Kim","year":"2015","unstructured":"Kim KH, Kim W, Howard TP, Vazquez F, Tsherniak A, Wu JN, et al. SWI\/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2. Nat Med. 2015;21(12):1491\u20136.","journal-title":"Nat Med"},{"issue":"3","key":"2718_CR345","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nm.3799","volume":"21","author":"BG Bitler","year":"2015","unstructured":"Bitler BG, Aird KM, Garipov A, Li H, Amatangelo M, Kossenkov AV, et al. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat Med. 2015;21(3):231\u20138.","journal-title":"Nat Med"},{"issue":"2","key":"2718_CR346","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/ijc.32118","volume":"145","author":"Q Liu","year":"2019","unstructured":"Liu Q, Wang G, Li Q, Jiang W, Kim JS, Wang R, et al. Polycomb group proteins EZH2 and EED directly regulate androgen receptor in advanced prostate cancer. Int J Cancer. 2019;145(2):415\u201326.","journal-title":"Int J Cancer"},{"key":"2718_CR347","doi-asserted-by":"publisher","first-page":"115200","DOI":"10.1016\/j.taap.2020.115200","volume":"404","author":"E Shankar","year":"2020","unstructured":"Shankar E, Franco D, Iqbal O, Moreton S, Kanwal R, Gupta S. Dual targeting of EZH2 and androgen receptor as a novel therapy for castration-resistant prostate cancer. Toxicol Appl Pharmacol. 2020;404:115200.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"23","key":"2718_CR348","doi-asserted-by":"publisher","first-page":"16168","DOI":"10.1021\/acs.jmedchem.3c01521","volume":"66","author":"X Yu","year":"2023","unstructured":"Yu X, Li D, Kottur J, Kim HS, Herring LE, Yu Y, et al. Discovery of potent and selective WDR5 proteolysis targeting chimeras as potential therapeutics for pancreatic cancer. J Med Chem. 2023;66(23):16168\u201386.","journal-title":"J Med Chem"},{"issue":"3","key":"2718_CR349","doi-asserted-by":"publisher","first-page":"108636","DOI":"10.1016\/j.celrep.2020.108636","volume":"34","author":"AD Guarnaccia","year":"2021","unstructured":"Guarnaccia AD, Rose KL, Wang J, Zhao B, Popay TM, Wang CE, et al. Impact of WIN site inhibitor on the WDR5 interactome. Cell Rep. 2021;34(3):108636.","journal-title":"Cell Rep"},{"issue":"13","key":"2718_CR350","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1182\/blood.2024024130","volume":"145","author":"Q Han","year":"2025","unstructured":"Han Q, Gu Y, Xiang H, Zhang L, Wang Y, Yang C, et al. Targeting WDR5\/ATAD2 signaling by the CK2\/IKAROS axis demonstrates therapeutic efficacy in T-ALL. Blood. 2025;145(13):1407\u201321.","journal-title":"Blood"},{"issue":"4","key":"2718_CR351","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1021\/acschembio.3c00108","volume":"18","author":"L Liu","year":"2023","unstructured":"Liu L, Shen L, Ding Z, He M, Li E, Tallarico JA, et al. Mechanism of resistance to the WDR5 inhibitor in MLL-rearranged leukemia. ACS Chem Biol. 2023;18(4):949\u201358.","journal-title":"ACS Chem Biol"},{"issue":"2","key":"2718_CR352","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ccell.2023.12.016","volume":"42","author":"C Pacini","year":"2024","unstructured":"Pacini C, Duncan E, Gon\u00e7alves E, Gilbert J, Bhosle S, Horswell S, et al. A comprehensive clinically informed map of dependencies in cancer cells and framework for target prioritization. Cancer Cell. 2024;42(2):301-16.e9.","journal-title":"Cancer Cell"},{"issue":"10","key":"2718_CR353","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114775","volume":"43","author":"C Abecunas","year":"2024","unstructured":"Abecunas C, Kidd AD, Jiang Y, Zong H, Fallahi-Sichani M. Multivariate analysis of metabolic state vulnerabilities across diverse cancer contexts reveals synthetically lethal associations. Cell Rep. 2024;43(10):114775.","journal-title":"Cell Rep"},{"issue":"7","key":"2718_CR354","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1021\/acsmedchemlett.3c00104","volume":"14","author":"A Vulpetti","year":"2023","unstructured":"Vulpetti A, Holzer P, Schmiedeberg N, Imbach-Weese P, Pissot-Soldermann C, Hollingworth GJ, et al. Discovery of new binders for DCAF1, an emerging ligase target in the targeted protein degradation field. ACS Med Chem Lett. 2023;14(7):949\u201354.","journal-title":"ACS Med Chem Lett"},{"issue":"D1","key":"2718_CR355","doi-asserted-by":"publisher","first-page":"D1450","DOI":"10.1093\/nar\/gkad862","volume":"52","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Zhou Y, Zhou Y, Yu X, Shen X, Hong Y, et al. TheMarker: a comprehensive database of therapeutic biomarkers. Nucleic Acids Res. 2024;52(D1):D1450\u201364.","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"2718_CR356","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","volume":"35","author":"MF Mosele","year":"2024","unstructured":"Mosele MF, Westphalen CB, Stenzinger A, Barlesi F, Bayle A, Bi\u00e8che I, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2024;35(7):588\u2013606.","journal-title":"Ann Oncol"},{"issue":"1","key":"2718_CR357","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1038\/s42003-025-08491-0","volume":"8","author":"SW Kimani","year":"2025","unstructured":"Kimani SW, Noureldin M, Wilson B, Hoffer L, Green SR, Szewczyk MM, et al. OICR-41103 as a chemical probe for the DCAF1 WD40 domain. Commun Biol. 2025;8(1):1076.","journal-title":"Commun Biol"},{"issue":"4","key":"2718_CR358","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1158\/1541-7786.MCR-24-0933","volume":"23","author":"I Silverman","year":"2025","unstructured":"Silverman I, Shaykevich A, Maitra R. The role of WDR77 in cancer: more than a PRMT5 interactor. Mol Cancer Res. 2025;23(4):269\u201376.","journal-title":"Mol Cancer Res"},{"issue":"8060","key":"2718_CR359","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/s41586-025-08815-4","volume":"640","author":"J Fielden","year":"2025","unstructured":"Fielden J, Siegner SM, Gallagher DN, Schr\u00f6der MS, Dello Stritto MR, Lam S, et al. Comprehensive interrogation of synthetic lethality in the DNA damage response. Nature. 2025;640(8060):1093\u2013102.","journal-title":"Nature"},{"key":"2718_CR360","doi-asserted-by":"publisher","first-page":"218013","DOI":"10.1016\/j.canlet.2025.218013","volume":"633","author":"L Wang","year":"2025","unstructured":"Wang L, Chen X, Qu R, Shao S, Gong L, Li T, et al. UBE2C promotes pancreatic tumorigenesis by KRAS stabilization via APC\/C(CDH1)-mediated WDR76 degradation. Cancer Lett. 2025;633:218013.","journal-title":"Cancer Lett"},{"issue":"1","key":"2718_CR361","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1038\/s41467-024-47701-x","volume":"15","author":"P Romero","year":"2024","unstructured":"Romero P, Richart L, Aflaki S, Petitalot A, Burton M, Michaud A, et al. EZH2 mutations in follicular lymphoma distort H3K27me3 profiles and alter transcriptional responses to PRC2 inhibition. Nat Commun. 2024;15(1):3452.","journal-title":"Nat Commun"},{"issue":"11","key":"2718_CR362","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1038\/s43018-024-00838-6","volume":"5","author":"R Romero","year":"2024","unstructured":"Romero R, Chu T, Gonz\u00e1lez Robles TJ, Smith P, Xie Y, Kaur H, et al. The neuroendocrine transition in prostate cancer is dynamic and dependent on ASCL1. Nat Cancer. 2024;5(11):1641\u201359.","journal-title":"Nat Cancer"},{"issue":"8095","key":"2718_CR363","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41586-025-09727-z","volume":"649","author":"JJ Li","year":"2026","unstructured":"Li JJ, Vasciaveo A, Karagiannis D, Sun Z, Gretarsson KH, Chen X, et al. NSD2 targeting reverses plasticity and drug resistance in prostate cancer. Nature. 2026;649(8095):216\u201326.","journal-title":"Nature"},{"issue":"1","key":"2718_CR364","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41389-023-00477-z","volume":"12","author":"LA Bumpous","year":"2023","unstructured":"Bumpous LA, Moe KC, Wang J, Carver LA, Williams AG, Romer AS, et al. WDR5 facilitates recruitment of N-MYC to conserved WDR5 gene targets in neuroblastoma cell lines. Oncogenesis. 2023;12(1):32.","journal-title":"Oncogenesis"},{"issue":"1","key":"2718_CR365","doi-asserted-by":"publisher","first-page":"7609","DOI":"10.1038\/s41467-024-51424-4","volume":"15","author":"F Nadalin","year":"2024","unstructured":"Nadalin F, Marzi MJ, Pirra Piscazzi M, Fuentes-Bravo P, Procaccia S, Climent M, et al. Multi-omic lineage tracing predicts the transcriptional, epigenetic and genetic determinants of cancer evolution. Nat Commun. 2024;15(1):7609.","journal-title":"Nat Commun"},{"issue":"1","key":"2718_CR366","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s43556-025-00352-w","volume":"6","author":"J Li","year":"2025","unstructured":"Li J, Hu J, Yang Y, Zhang H, Liu Y, Fang Y, et al. Drug resistance in cancer: molecular mechanisms and emerging treatment strategies. Mol Biomed. 2025;6(1):111.","journal-title":"Mol Biomed"},{"issue":"12","key":"2718_CR367","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1038\/s41375-023-02050-4","volume":"37","author":"JP Bewersdorf","year":"2023","unstructured":"Bewersdorf JP, Stahl M, Taylor J, Mi X, Chandhok NS, Watts J, et al. E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial. Leukemia. 2023;37(12):2512\u20136.","journal-title":"Leukemia"},{"issue":"3","key":"2718_CR368","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1021\/acschembio.2c00804","volume":"18","author":"FM Bashore","year":"2023","unstructured":"Bashore FM, Foley CA, Ong HW, Rectenwald JM, Hanley RP, Norris-Drouin JL, et al. PROTAC Linkerology Leads to an Optimized Bivalent Chemical Degrader of Polycomb Repressive Complex 2 (PRC2) Components. ACS Chem Biol. 2023;18(3):494\u2013507.","journal-title":"ACS Chem Biol"},{"key":"2718_CR369","doi-asserted-by":"publisher","first-page":"2763168","DOI":"10.1155\/2023\/2763168","volume":"2023","author":"G Shi","year":"2023","unstructured":"Shi G, Ni Q, Miao Y, Huang H, Yin Z, Shi W, et al. Identification of WD-Repeat Protein 72 as a novel prognostic biomarker in non-small-cell lung cancer. Mediators Inflamm. 2023;2023:2763168.","journal-title":"Mediators Inflamm"},{"key":"2718_CR370","doi-asserted-by":"crossref","unstructured":"Shi Z, Liu Y, Zhao L, Chen L, Yang Q, Xiao M. WDR49 mutation as a novel predictive biomarker in patients with non\u2013small cell lung cancer with immune checkpoint inhibitors. J Clin Oncol. 2022;40:2615.","DOI":"10.1200\/JCO.2022.40.16_suppl.2615"},{"issue":"7","key":"2718_CR371","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.cell.2024.02.041","volume":"187","author":"A Passaro","year":"2024","unstructured":"Passaro A, Al Bakir M, Hamilton EG, Diehn M, Andr\u00e9 F, Roy-Chowdhuri S, et al. Cancer biomarkers: emerging trends and clinical implications for personalized treatment. Cell. 2024;187(7):1617\u201335.","journal-title":"Cell"},{"issue":"3","key":"2718_CR372","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1200\/JCO.20.01572","volume":"39","author":"DF Hayes","year":"2021","unstructured":"Hayes DF. Defining clinical utility of tumor biomarker tests: a clinician\u2019s viewpoint. J Clin Oncol. 2021;39(3):238\u201348.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2718_CR373","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s12672-025-02974-6","volume":"16","author":"H Yan","year":"2025","unstructured":"Yan H, Zhang L, Xu F, Chen T, Li R. Identification of DCAF5 as a novel cancer prognostic and immunotherapy biomarker through pan-cancer analysis and renal clear cell carcinoma clinical data validation. Discov Oncol. 2025;16(1):1119.","journal-title":"Discov Oncol"},{"issue":"6","key":"2718_CR374","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.annonc.2024.03.007","volume":"35","author":"X Wang","year":"2024","unstructured":"Wang X, Lamberti G, Di Federico A, Alessi J, Ferrara R, Sholl ML, et al. Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities. Ann Oncol. 2024;35(6):508\u201322.","journal-title":"Ann Oncol"},{"issue":"13","key":"2718_CR375","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","volume":"25","author":"L Marcus","year":"2019","unstructured":"Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. 2019;25(13):3753\u20138.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2718_CR376","doi-asserted-by":"publisher","first-page":"861","DOI":"10.21037\/tlcr-24-116","volume":"13","author":"T Tian","year":"2024","unstructured":"Tian T, Li Y, Li J, Xu H, Fan H, Zhu J, et al. Immunotherapy for patients with advanced non-small cell lung cancer harboring oncogenic driver alterations other than EGFR: a multicenter real-world analysis. Transl Lung Cancer Res. 2024;13(4):861\u201374.","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"2718_CR377","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s41392-024-01823-2","volume":"9","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Tao L, Qiu J, Xu J, Yang X, Zhang Y, et al. Tumor biomarkers for diagnosis, prognosis and targeted therapy. Signal Transduct Target Ther. 2024;9(1):132.","journal-title":"Signal Transduct Target Ther"},{"issue":"16","key":"2718_CR378","doi-asserted-by":"publisher","first-page":"4389","DOI":"10.1016\/j.cell.2024.05.039","volume":"187","author":"SR Savage","year":"2024","unstructured":"Savage SR, Yi X, Lei JT, Wen B, Zhao H, Liao Y, et al. Pan-cancer proteogenomics expands the landscape of therapeutic targets. Cell. 2024;187(16):4389-407.e15.","journal-title":"Cell"},{"key":"2718_CR379","doi-asserted-by":"publisher","first-page":"102089","DOI":"10.1016\/j.tranon.2024.102089","volume":"49","author":"Y Wang","year":"2024","unstructured":"Wang Y, Wu Q, Liu J, Wang X, Xie J, Fu X, et al. WDR77 in Pan-cancer: revealing expression patterns, genetic insights, and functional roles across diverse tumor types, with a spotlight on colorectal cancer. Transl Oncol. 2024;49:102089.","journal-title":"Transl Oncol"},{"issue":"3","key":"2718_CR380","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00428-025-04169-4","volume":"487","author":"EE Torlakovic","year":"2025","unstructured":"Torlakovic EE, Al Dieri R, Badrick T, Chen ZE, Cheung CC, Deans Z, et al. Indirect clinical validation for predictive biomarkers in oncology: International Quality Network for Pathology (IQN Path) Position Paper. Virchows Arch. 2025;487(3):565\u201372.","journal-title":"Virchows Arch"},{"issue":"6","key":"2718_CR381","doi-asserted-by":"publisher","first-page":"e111","DOI":"10.5858\/arpa.2023-0483-CP","volume":"148","author":"JD Goldsmith","year":"2024","unstructured":"Goldsmith JD, Troxell ML, Roy-Chowdhuri S, Colasacco CF, Edgerton ME, Fitzgibbons PL, et al. Principles of analytic validation of immunohistochemical assays: guideline update. Arch Pathol Lab Med. 2024;148(6):e111\u201353.","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"2718_CR382","doi-asserted-by":"publisher","first-page":"28264","DOI":"10.1038\/s41598-025-12780-3","volume":"15","author":"V Kushnarev","year":"2025","unstructured":"Kushnarev V, Stupichev D, Davitavyan S, Kriukov K, Shanthappa BU, Butusova A, et al. RNA sequencing and immunohistochemistry jointly improve tumor biomarker interpretation. Sci Rep. 2025;15(1):28264.","journal-title":"Sci Rep"},{"issue":"1","key":"2718_CR383","doi-asserted-by":"publisher","DOI":"10.1038\/s43856-025-00934-3","volume":"5","author":"A Yudina","year":"2025","unstructured":"Yudina A, Tazearslan C, Baisangurov A, Nuzhdina E, Lauziere K, Segodin V, et al. Clinical and analytical validation of a combined RNA and DNA exome assay across a large tumor cohort. Commun Med. 2025;5(1):236.","journal-title":"Commun Med"},{"issue":"1","key":"2718_CR384","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s41392-024-02021-w","volume":"9","author":"L Ma","year":"2024","unstructured":"Ma L, Guo H, Zhao Y, Liu Z, Wang C, Bu J, et al. Liquid biopsy in cancer current: status, challenges and future prospects. Signal Transduct Target Ther. 2024;9(1):336.","journal-title":"Signal Transduct Target Ther"},{"key":"2718_CR385","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.trsl.2024.05.014","volume":"272","author":"C Reina","year":"2024","unstructured":"Reina C, \u0160abanovi\u0107 B, Lazzari C, Gregorc V, Heeschen C. Unlocking the future of cancer diagnosis - promises and challenges of ctDNA-based liquid biopsies in non-small cell lung cancer. Transl Res. 2024;272:41\u201353.","journal-title":"Transl Res"},{"issue":"7","key":"2718_CR386","doi-asserted-by":"publisher","first-page":"101621","DOI":"10.1016\/j.xcrm.2024.101621","volume":"5","author":"H Yamaguchi","year":"2024","unstructured":"Yamaguchi H, Hsu JM, Sun L, Wang SC, Hung MC. Advances and prospects of biomarkers for immune checkpoint inhibitors. Cell Rep Med. 2024;5(7):101621.","journal-title":"Cell Rep Med"},{"issue":"10","key":"2718_CR387","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1080\/15592294.2021.1999006","volume":"17","author":"L Xiao","year":"2022","unstructured":"Xiao L, Dang Y, Hu B, Luo L, Zhao P, Wang S, et al. Overlapping functions of RBBP4 and RBBP7 in regulating cell proliferation and histone H3.3 deposition during mouse preimplantation development. Epigenetics. 2022;17(10):1205\u201318.","journal-title":"Epigenetics"},{"issue":"11","key":"2718_CR388","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1111\/febs.15585","volume":"288","author":"Y Bi","year":"2021","unstructured":"Bi Y, Cui D, Xiong X, Zhao Y. The characteristics and roles of \u03b2-TrCP1\/2 in carcinogenesis. FEBS J. 2021;288(11):3351\u201374.","journal-title":"FEBS J"},{"issue":"8","key":"2718_CR389","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1038\/s43018-024-00789-y","volume":"5","author":"X Shi","year":"2024","unstructured":"Shi X, Gekas C, Verduzco D, Petiwala S, Jeffries C, Lu C, et al. Building a translational cancer dependency map for the cancer genome atlas. Nat Cancer. 2024;5(8):1176\u201394.","journal-title":"Nat Cancer"},{"issue":"1","key":"2718_CR390","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1038\/s41467-021-21478-9","volume":"12","author":"NA Thompson","year":"2021","unstructured":"Thompson NA, Ranzani M, van der Weyden L, Iyer V, Offord V, Droop A, et al. Combinatorial CRISPR screen identifies fitness effects of gene paralogues. Nat Commun. 2021;12(1):1302.","journal-title":"Nat Commun"},{"issue":"1","key":"2718_CR391","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41568-024-00763-x","volume":"25","author":"R Arafeh","year":"2025","unstructured":"Arafeh R, Shibue T, Dempster JM, Hahn WC, Vazquez F. The present and future of the cancer dependency map. Nat Rev Cancer. 2025;25(1):59\u201373.","journal-title":"Nat Rev Cancer"},{"issue":"7873","key":"2718_CR392","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583\u20139.","journal-title":"Nature"},{"issue":"7873","key":"2718_CR393","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/s41586-021-03828-1","volume":"596","author":"K Tunyasuvunakool","year":"2021","unstructured":"Tunyasuvunakool K, Adler J, Wu Z, Green T, Zielinski M, \u017d\u00eddek A, et al. Highly accurate protein structure prediction for the human proteome. Nature. 2021;596(7873):590\u20136.","journal-title":"Nature"},{"issue":"8016","key":"2718_CR394","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","volume":"630","author":"J Abramson","year":"2024","unstructured":"Abramson J, Adler J, Dunger J, Evans R, Green T, Pritzel A, et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature. 2024;630(8016):493\u2013500.","journal-title":"Nature"},{"issue":"7","key":"2718_CR395","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/s44320-025-00121-5","volume":"21","author":"SN Fischer","year":"2025","unstructured":"Fischer SN, Claussen ER, Kourtis S, Sdelci S, Orchard S, Hermjakob H, et al. hu.MAP3.0: atlas of human protein complexes by integration of >25,000 proteomic experiments. Mol Syst Biol. 2025;21(7):911\u201343.","journal-title":"Mol Syst Biol."},{"issue":"2","key":"2718_CR396","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41594-022-00910-8","volume":"30","author":"DF Burke","year":"2023","unstructured":"Burke DF, Bryant P, Barrio-Hernandez I, Memon D, Pozzati G, Shenoy A, et al. Towards a structurally resolved human protein interaction network. Nat Struct Mol Biol. 2023;30(2):216\u201325.","journal-title":"Nat Struct Mol Biol"},{"issue":"1","key":"2718_CR397","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1038\/s41467-018-03523-2","volume":"9","author":"X Liu","year":"2018","unstructured":"Liu X, Salokas K, Tamene F, Jiu Y, Weldatsadik RG, \u00d6hman T, et al. An AP-MS- and BioID-compatible MAC-tag enables comprehensive mapping of protein interactions and subcellular localizations. Nat Commun. 2018;9(1):1188.","journal-title":"Nat Commun"},{"issue":"4","key":"2718_CR398","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/s44320-024-00019-8","volume":"20","author":"P Trepte","year":"2024","unstructured":"Trepte P, Secker C, Olivet J, Blavier J, Kostova S, Maseko SB, et al. AI-guided pipeline for protein-protein interaction drug discovery identifies a SARS-CoV-2 inhibitor. Mol Syst Biol. 2024;20(4):428\u201357.","journal-title":"Mol Syst Biol"},{"issue":"1","key":"2718_CR399","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s10238-025-01965-9","volume":"26","author":"CY Hsu","year":"2025","unstructured":"Hsu CY, Askar S, Alshkarchy SS, Nayak PP, Attabi KAL, Khan MA, et al. AI-driven multi-omics integration in precision oncology: bridging the data deluge to clinical decisions. Clin Exp Med. 2025;26(1):29.","journal-title":"Clin Exp Med"},{"issue":"1","key":"2718_CR400","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s43556-025-00340-0","volume":"6","author":"Z Jiang","year":"2025","unstructured":"Jiang Z, Zhang H, Gao Y, Sun Y. Multi-omics strategies for biomarker discovery and application in personalized oncology. Mol Biomed. 2025;6(1):115.","journal-title":"Mol Biomed"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02718-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02718-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02718-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:02:53Z","timestamp":1789736573000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-026-02718-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":400,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2718"],"URL":"https:\/\/doi.org\/10.1186\/s12943-026-02718-2","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]},"assertion":[{"value":"12 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors consent to publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"220"}}